The study focus the lecturer posted comes first (Lectures 37–38), then criteria, scores and classifications: one table per set from the slides, each with a labeled memory aid. Respiratory Block Exam I, condensed from the Exam 6 study guide. Lectures covered: 33 (oxygen delivery), 34 (acid-base part I), 35 (asthma), 36 (chronic obstructive pulmonary disease), 37 (respiratory infections and vaccines), 38 (mycobacterial infections including tuberculosis). Each lecture opens with a gold card of what its lecturer stressed on the recording (starred); every fact still comes from the slides.
| Focus point | Know this |
|---|---|
| PREVENTION & VACCINES | |
| Influenza product selection | Yearly for everyone 6 months or older without a contraindication; 65 or older: preferentially high-dose, adjuvanted or recombinant; pregnancy: inactivated or recombinant, avoid live attenuated; egg allergy: routine safety measures only |
| Respiratory syncytial virus (RSV) eligibility | One dose: all adults 75 or older, and 50–74 at increased risk; not an annual vaccine |
| Pneumococcal sequencing | Conjugate-naive eligible adult: PCV20 or PCV21 alone completes the series; PCV15 is followed by PPSV23, usually 1 year or more later (PCV = pneumococcal conjugate vaccine, PPSV23 = 23-valent polysaccharide vaccine) |
| BRONCHITIS & STEWARDSHIP | |
| Bronchitis or pneumonia? | Uncomplicated bronchitis is clinical and usually viral; abnormal vital signs, hypoxemia, fever or focal consolidation → chest film for pneumonia |
| Sputum color | Green or yellow sputum does not justify antibiotics; no routine antibiotics for uncomplicated bronchitis |
| COMMUNITY-ACQUIRED PNEUMONIA (CAP) | |
| Confirmation and site of care | Chest radiograph confirms (lung ultrasound with expertise); Pneumonia Severity Index plus judgment for outpatient versus general ward; severe CAP gets urgent intensive care-level assessment |
| Severe CAP | Vasopressor-dependent shock, mechanical ventilation, or 3 or more minor criteria |
| Outpatient regimens | No comorbidities: amoxicillin or doxycycline (macrolide alone only if pneumococcal resistance below 25%). Comorbidities: amoxicillin-clavulanate, cefpodoxime or cefuroxime plus azithromycin or doxycycline, or a respiratory fluoroquinolone |
| Resistant coverage | Methicillin-resistant Staphylococcus aureus or Pseudomonas coverage only for validated risk (prior respiratory isolation, recent hospitalization with intravenous antibiotics) |
| HOSPITAL-ACQUIRED (HAP) & VENTILATOR-ASSOCIATED (VAP) PNEUMONIA, ASPIRATION | |
| Timing, cultures, antibiogram | HAP: 48 hours or more after admission; VAP: more than 48 hours after intubation. Respiratory cultures first, then empiric therapy by the local antibiogram (cefepime or piperacillin-tazobactam); do not delay care in unstable patients |
| De-escalation | Narrow or stop as cultures and the course clarify; usually 7 days |
| Pneumonitis vs aspiration pneumonia | Pneumonitis: sterile chemical injury, support, no prophylactic antibiotics when bacterial infection is not suspected. Pneumonia: infection, CAP or HAP regimen by setting. Anaerobic coverage only for abscess or empyema |
| OPPORTUNISTIC & ATYPICAL | |
| Pneumocystis jirovecii pneumonia (PJP): sampling and PCR | Induced sputum or bronchoalveolar lavage (expectorated sputum: poor sensitivity); polymerase chain reaction (PCR) is highly sensitive but can detect colonization |
| Steroid thresholds | Human immunodeficiency virus (HIV)-associated PJP: adjunctive corticosteroids if room-air arterial oxygen below 70 mm Hg or alveolar-arterial oxygen gradient 35 mm Hg or more |
| Histoplasmosis by severity | Mild acute, immunocompetent: often observe, no antifungal; prolonged or progressive, or higher-risk host: consider itraconazole; severe or disseminated: specialist-led amphotericin-based induction; chronic cavitary: azole, usually 12 months or more |
| Psittacosis | Bird exposure; respiratory nucleic acid test; doxycycline preferred (macrolide with infectious disease input if tetracyclines are unsuitable) |
| INFLUENZA & COVID-19 | |
| Negative rapid influenza test | Does not exclude influenza, especially with high activity; do not withhold indicated antivirals |
| High-risk influenza | Oseltamivir promptly, even after 48 hours |
| COVID-19 pathways | No hypoxemia, high-risk outpatient: nirmatrelvir/ritonavir within 5 days or 3-day remdesivir within 7 days; no systemic steroids unless another indication exists. Hypoxemic inpatient: dexamethasone, consider remdesivir; baricitinib or tocilizumab for rapid progression; venous thromboembolism prophylaxis |
| Best study method | For each topic, practice the same five decisions: diagnosis, severity/site of care, the test that changes management, first-line treatment, and when to withhold or narrow therapy |
| Focus point | Know this |
|---|---|
| Smear ≠ species | A positive acid-fast smear cannot tell tuberculosis from nontuberculous mycobacteria; confirm the species with molecular testing and culture |
| Right infection test | Prefer the interferon-gamma release assay after BCG (bacille Calmette-Guérin); in human immunodeficiency virus (HIV) infection or a recent close contact, skin test induration 5 mm or more is positive and needs evaluation for active disease |
| Rule out active tuberculosis first | Skin and blood tests show infection, not latent versus active: clinical evaluation and chest imaging before preventive therapy |
| Right specimens | 3 sputum specimens, 8–24 hours apart, 1 early morning; acid-fast smear and culture plus 1 rapid molecular test |
| Exposure and suspicion | Repeat an early negative test 8–10 weeks after the last exposure; suspected pulmonary tuberculosis: immediate airborne isolation and tuberculosis-program coordination |
| Mycobacterium avium complex (MAC) | One isolate is not enough: symptoms, imaging and usually 2 or more same-species sputum cultures; azithromycin + ethambutol + a rifamycin for 12 months or more after culture conversion |
The slide’s numbers, in order: 5 · 3 · 8–24 · 1 · 8–10 · 2+ · 12+.
5 mm skin test cut-off in HIV or a recent close contact3 sputum specimens8–24 hours between specimens1 early-morning specimen (and 1 rapid molecular test)8–10 weeks after the last exposure to repeat an early negative test2+ usually 2 or more same-species sputum cultures for MAC12+ at least 12 months of MAC treatment after culture conversion
Where it breaks: The 1 stands for two things on the slide: one early-morning sample and one rapid molecular test.
| Side | What slide 3 lists |
|---|---|
| Indications | Hypoxia · acute medical/surgical needs (perioperative/postoperative period) · respiratory conditions (carbon monoxide poisoning) · special indications: air hunger, cluster headache |
| Benefits | Correction of hypoxia · symptom relief · therapeutic benefits |
| Risks | Hypercapnia/carbon dioxide retention · fire hazard! · mucosal irritation · vasoconstriction (remember, not given in myocardial infarction unless oxygen saturation < 91%) |
| Slide 3 gives the myocardial infarction cut-off as below 91%; the slide’s 91% is the value tested. | |
Hypoxic Patients Can Accept Cannulas — but Fire Has Many Victims.
H HypoxiaP Perioperative/postoperative (acute medical or surgical need)C Carbon monoxide poisoningA Air hungerC Cluster headacheF Fire hazardH Hypercapnia (carbon dioxide retention)M Mucosal irritationV Vasoconstriction: not in myocardial infarction unless saturation is below 91%
Where it breaks: The benefits row (correction of hypoxia, symptom relief, therapeutic benefit) is not in the aid. Air hunger and cluster headache are listed apart, as the special indications.
| Situation (slide 6) | Qualifying criteria (arterial oxygen = partial pressure of oxygen in arterial blood) | Result |
|---|---|---|
| Resting (room air) | Arterial oxygen ≤ 55 mm Hg or saturation ≤ 88% | Group I qualification |
| Resting (conditional) | Arterial oxygen 56–59 mm Hg or saturation = 89% + evidence of pulmonary hypertension, cor pulmonale, or hematocrit > 56% | Group II qualification |
| During sleep | Arterial oxygen ≤ 55 mm Hg or saturation ≤ 88% with a ≥ 5% drop from baseline | Qualifies for nocturnal oxygen |
| During exertion | Arterial oxygen ≤ 55 mm Hg or saturation ≤ 88% during exercise and improves with oxygen | Qualifies for ambulatory oxygen |
| Recertification | Group I: 12 months · Group II: 3 months | Repeat testing required |
| Slide 5: document hypoxia by arterial blood gas or pulse oximetry during rest, exertion and/or sleep, performed at the time of need; saturation values are on room air. Slide 5 names the Group II blood finding “polycythemia” and lists only saturation for sleep and exertion; slide 6’s picture gives hematocrit > 56% and adds the arterial oxygen alternative. | ||
55 and 88 qualify outright (Group I, renew yearly); 56–59 or 89 need a second finding (Group II, renew every 3 months).
55 / 88 Group I at rest: arterial oxygen 55 or less, or saturation 88% or less56–59 / 89 + sign Group II: plus pulmonary hypertension, cor pulmonale or hematocrit above 56%Sleep 88% or less with a drop of 5% or moreExertion 88% or less and improves with oxygen12 vs 3 Group I recertifies at 12 months, Group II at 3
Where it breaks: The sleep and exertion rows use the Group I numbers but add a condition: a drop of 5% or more from baseline during sleep, improvement with oxygen during exertion.
| Flow (L/min) | Fraction of inspired oxygen (slide 9) |
|---|---|
| Room air | .21 or 21% |
| 1 | .24 or 24% |
| 2 | .28 or 28% |
| 3 | .32 or 32% |
| 4 | .36 or 36% |
| 5 | .40 or 40% |
| 6 | .44 or 44% |
| Slide 11: low flow device, most commonly used in mild hypoxia; each 1 L increase adds 4%; the knob turns above 6 L/min but the fraction maxes out at 44%. Slide 9: humidity is used with flow rates greater than 4 L/min. Slide 9 prints the range as “.24% to .44%”; its own list shows .24 to .44, that is 24% to 44%. | |
Start at 20 and add 4 per liter: 24, 28, 32, 36, 40, 44.
21 room air+4 each liter adds 4%6 L = 44% the ceiling: no gain above 6 L/min> 4 L add humidity
Where it breaks: The count starts from 20, not room air’s 21: 1 L/min is 24%, not 25%.
| Oxygen setting (slide 13) | Fraction of inspired oxygen |
|---|---|
| 5–6 L/min | 35% |
| 6–7 L/min | 40% |
| 7–8 L/min | 50% |
| Slide 13: low flow device, set between 5 and 10 L/min, used in mild to moderate respiratory distress. The slide 20 table gives the simple mask .35–.50 at 5–10 L/min. | |
35, 40, 50: the mask’s three steps sit between 5 and 8 L/min.
5–6 35%6–7 40%7–8 50%
Where it breaks: The steps are uneven (+5, then +10), and the mask starts at 5 L/min, inside the cannula’s 1–6 L/min range.
| Device | Flow type | Fraction (slide 20) | Flow (slide 20) | Delivered fraction (slide 8) |
|---|---|---|---|---|
| Nasal cannula | Low flow (slide 11) | .24–.44 (slide 9) | 1–6 L/min (slide 9) | Varies with respiration rate, inspiratory flow and tidal volume |
| Simple mask | Low flow (slide 13) | .35–.50 | 5–10 L/min | Varies with respiration rate, inspiratory flow and tidal volume |
| Partial rebreather mask | — | .40–.70 | At least 10 L/min | Varies with patient demand |
| Non-rebreather mask | Low flow device, but with high fraction (slide 15) | .60–1.0 | At least 10 L/min (slide 15: 10–15 L/min = 60–100%) | Varies with patient demand |
| Venturi mask | High flow (slide 16) | .24–.50 | Variable (slide 16: 4–10 L/min) | Precise: the port chosen sets the fraction (slide 16) |
| Air-entrainment nebulizer | — | .21–1.0 | Variable | Fixed (air entrainment): does not fluctuate |
| Partial rebreather: slide 14 says it delivers 60–80%; the slide 20 table says .40–.70. Not tested either way. | ||||
| Air-entrainment nebulizer (aerosol mask, open face mask, T-piece, tracheostomy collar): slide 17 says .28–1.0, can deliver higher but not recommended above .50; slide 20 says .21–1.0. | ||||
| Slide 17: non-rebreather flow must prevent bag collapse on inspiration; Venturi total flow should be higher than inspiratory demand. Non-rebreather = severely hypoxic patients still ventilating well (slide 15); Venturi = often chronic obstructive pulmonary disease, for precision (slide 16). | ||||
Venturi is Precise and the entrainment nebulizer Fixed; everything else Varies. Ceiling ladder: cannula 44, mask 50, partial 70, non-rebreather 100.
Cannula .24–.44 at 1–6 L/minSimple mask .35–.50 at 5–10 L/minPartial rebreather .40–.70, at least 10 L/minNon-rebreather .60–1.0, at least 10 L/minVenturi .24–.50, precise (ports), high flowAir-entrainment nebulizer .21–1.0, fixed, not above .50 (slide 17)
Where it breaks: The Venturi mask and the air-entrainment nebulizer sit off the ladder: the Venturi mask is set precisely by its ports (slide 16), and the air-entrainment system gives a fixed fraction (slide 8).
| Measurement (slide 6) | Arterial blood | Venous blood |
|---|---|---|
| pH (range) | 7.40 (7.35–7.45) | 7.36 (7.31–7.41) |
| Partial pressure of oxygen, mm Hg (decreases with age) | 80–100 | 30–50 |
| Partial pressure of carbon dioxide, mm Hg | 36–44 | 40–52 |
| Oxygen saturation, % (decreases with age) | > 95 | 60–85 |
| Bicarbonate, mEq/L | 22–26 | 22–28 |
| Base difference (deficit/excess) | −2 to +2 | −2 to +2 |
| Slide 3: acidemia = pH < 7.35, alkalemia = pH > 7.45; acidosis and alkalosis are the pathologic conditions behind them. Slide 5 repeats the arterial pH, carbon dioxide and bicarbonate ranges. | ||
Arterial gas = 7.40, 40, 24, each give or take a little: pH ± 0.05, carbon dioxide ± 4, bicarbonate ± 2.
7.40 ± 0.05 pH 7.35–7.4540 ± 4 carbon dioxide 36–44 mm Hg24 ± 2 bicarbonate 22–26 mEq/L80–100 arterial oxygen pressure> 95 arterial saturation± 2 base difference, arterial and venous alike
Where it breaks: The venous column does not follow the pattern: lower pH, higher carbon dioxide, far lower oxygen. Oxygen pressure and saturation fall with age.
| pH | Meaning |
|---|---|
| < 7.35 | Acidemia |
| 7.35–7.45 | Normal systemic arterial pH |
| > 7.45 | Alkalemia |
| < 6.7 or > 7.6 | Unsustainable: may cause cardiac hypocontractility/irritability, seizures, cerebral edema, metabolic disturbances; may warrant therapy to normalize serum pH along with treatment of the underlying cause |
| Slide 8’s 6.7 and 7.6 are the values tested. | |
The survival limits are mirror images: 6.7 and 7.6, the same two digits swapped.
Below 7.35 acidemia7.35–7.45 normalAbove 7.45 alkalemia6.7 / 7.6 unsustainable: may warrant therapy to normalize the pH, along with the cause
Where it breaks: The swap is lopsided: 6.7 sits 0.65 below the normal floor, 7.6 only 0.15 above the ceiling.
| Disorder (slide 59) | Primary defect | Compensatory response | Magnitude of compensation |
|---|---|---|---|
| Respiratory acidosis, acute | ↑ carbon dioxide | ↑ bicarbonate | ↑ bicarbonate 1 mEq/L per 10 mm Hg ↑ carbon dioxide |
| Respiratory acidosis, chronic | ↑ carbon dioxide | ↑ bicarbonate | ↑ bicarbonate 3.5 mEq/L per 10 mm Hg ↑ carbon dioxide |
| Respiratory alkalosis, acute | ↓ carbon dioxide | ↓ bicarbonate | ↓ bicarbonate 2 mEq/L per 10 mm Hg ↓ carbon dioxide |
| Respiratory alkalosis, chronic | ↓ carbon dioxide | ↓ bicarbonate | ↓ bicarbonate 5 mEq/L per 10 mm Hg ↓ carbon dioxide |
| Metabolic acidosis | ↓ bicarbonate | ↓ carbon dioxide | ↓ carbon dioxide 1.3 mm Hg per 1 mEq/L ↓ bicarbonate |
| Metabolic alkalosis | ↑ bicarbonate | ↑ carbon dioxide | ↑ carbon dioxide 0.75 mm Hg per 1 mEq/L ↑ bicarbonate |
| Slide 22: renal compensation for respiratory acidosis begins 6–12 hours after onset; complete compensation may take days. Slide 38: in metabolic alkalosis carbon dioxide is rarely above 55 mm Hg; if higher, consider a concurrent primary respiratory acidosis. | |||
| Slide 59 gives 3.5 for chronic respiratory acidosis; on the recording the lecturer rounded it to 4 for the math. Questions give these ratios when they are needed. | |||
Respiratory: acid 1 then 3.5, alkali 2 then 5 (per 10, acute then chronic). Metabolic: acid 1.3, alkali 0.75 (per 1).
1 acute respiratory acidosis3.5 chronic respiratory acidosis2 acute respiratory alkalosis5 chronic respiratory alkalosis1.3 metabolic acidosis (carbon dioxide falls)0.75 metabolic alkalosis (carbon dioxide rises)
Where it breaks: Respiratory ratios are bicarbonate per 10 mm Hg of carbon dioxide; metabolic ratios flip to carbon dioxide per 1 mEq/L of bicarbonate. For the respiratory disorders, chronic is the bigger number (slide 22: renal compensation begins in 6–12 hours and may take days).
| Disorder | Expected carbon dioxide | If the actual carbon dioxide is higher |
|---|---|---|
| Metabolic acidosis (slide 58) | Winter’s formula: expected PaCO2 (arterial carbon dioxide) = 1.5 (measured bicarbonate) + 8 ± 2 | Metabolic acidosis together with respiratory acidosis; can be a sign of impending respiratory failure |
| Metabolic alkalosis (slide 38) | Rises (decreased ventilation to retain carbon dioxide), rarely above 55 mm Hg | Above 55: consider a concurrent primary respiratory acidosis |
“One and a half, plus eight, give or take two”; and alkalosis tops out at 55.
1.5 × bicarbonate + 8 ± 2 expected carbon dioxide in metabolic acidosis55 the ceiling for compensation in metabolic alkalosis
Where it breaks: Both rows only flag a carbon dioxide that is too HIGH (added respiratory acidosis); the slides give no reading for one that is too low.
| Item | Slide wording |
|---|---|
| Formula (slide 47) | Anion gap = sodium − (chloride + bicarbonate) |
| Normal (slide 47) | 9–15 |
| Elevated (slide 48) | Usually an increase in unmeasured anions; less often a decrease in unmeasured cations (calcium, magnesium, potassium, gamma-globulins) |
| Normal gap (slide 49) | Does not exclude acidosis or a high unmeasured anion concentration; should not override clinical concern |
| Causes for error (slide 49) | Hypoalbuminemia · hypernatremia/hyponatremia · antibiotics |
| Slide 47 prints the normal range as “9-15*”; the asterisk is not explained on the slide. | |
Sodium minus the two big anions, 9 to 15; and the gap lies when ASA: Albumin low, Sodium off, Antibiotics.
Na − (Cl + HCO3) sodium minus (chloride + bicarbonate)9–15 normalUp more unmeasured anions, or fewer unmeasured cationsNormal gap still may be acidosisA Albumin low (hypoalbuminemia)S Sodium high or lowA Antibiotics
Where it breaks: ASA is only the error list; the gap-raising cations (calcium, magnesium, potassium, gamma-globulins) are a separate list.
| Letter | Cause (slide 55) |
|---|---|
| M | Methanol, metformin |
| U | Uremia |
| D | Diabetic ketoacidosis |
| P | Paraldehyde |
| I | Isoniazid, iron |
| L | Lactic acidosis |
| E | Ethylene glycol |
| S | Salicylates, starvation |
| Slide 55: think about metabolic anions and drug/chemical anions. The slide spells “Isoniazide” and “Ethelyne glycol”. | |
MUDPILES (the slide’s own aid; its picture is a pile of mud).
M methanol, metforminU uremiaD diabetic ketoacidosisP paraldehydeI isoniazid, ironL lactic acidosisE ethylene glycolS salicylates, starvation
Where it breaks: Three letters carry two causes each (M, I, S): the second ones (metformin, iron, starvation) are the ones forgotten.
| Letter | Cause (slide 56) |
|---|---|
| U | Ureteral diversion |
| S | Saline infusion |
| E | Exogenous acid |
| D | Diarrhea |
| C | Carbonic anhydrase inhibitors |
| A | Adrenal insufficiency |
| R | Renal tubular acidosis |
| Slide 56: think about loss of bicarbonate, chloride retention, and acids (hydrochloric acid equivalents, ammonium chloride). | |
USEDCAR (the slide’s own aid; its picture is a rusted old truck).
U ureteral diversionS saline infusionE exogenous acidD diarrheaC carbonic anhydrase inhibitorsA adrenal insufficiencyR renal tubular acidosis
Where it breaks: Every letter is one cause; sort them by the slide’s three themes: bicarbonate lost (diarrhea, ureteral diversion, carbonic anhydrase inhibitors), chloride kept (saline), acid added (exogenous acid).
| Type | Urine chloride (slide 41) | Causes (slides 42–43) | Treatment (slide 44) |
|---|---|---|---|
| Saline responsive (more common): sign of extracellular volume contraction | Lower: < 25 mEq/L | Diuretic therapy · post-hypercapnia · loss of hydrochloric acid (vomiting/nasogastric suction) · antacids · volume contraction | Treat underlying cause; isotonic saline; discontinue diuretics |
| Saline unresponsive (elevated bicarbonate with euvolemia/hypervolemia, slide 37), normotensive | Higher: > 40 mEq/L | Severe potassium depletion · hypoparathyroidism and hypercalcemia | Treat underlying cause |
| Saline unresponsive, hypertensive | Higher: > 40 mEq/L | Primary aldosteronism · exogenous alkali · mineralocorticoids · licorice | Treat underlying cause |
| Slide 43 files exogenous alkali (spelled “alkalai”) under the hypertensive group. Never decided by blood pressure group. | |||
Under 25, saline revives; over 40, take the blood pressure. Hypertensive = MEAL.
< 25 saline responsive: give isotonic saline, stop diuretics> 40, normal pressure potassium depletion; hypoparathyroidism and hypercalcemiaM MineralocorticoidsE Exogenous alkaliA Aldosteronism (primary)L Licorice
Where it breaks: Urine chloride between 25 and 40 is not assigned on the slide. MEAL holds exogenous alkali only because slide 43 puts it there.
| Arterial pH | Arterial carbon dioxide | Reading | Next step (slide 63) |
|---|---|---|---|
| < 7.4 (acidosis) | > 40 mm Hg | Respiratory acidosis | Determine whether the lung disorder is acute or chronic |
| < 7.4 (acidosis) | < 40 mm Hg | Compensation for metabolic acidosis | Check for ↑ anion gap; check clinical history for renal, gastrointestinal and systemic causes |
| > 7.4 (alkalosis) | > 40 mm Hg | Compensation for metabolic alkalosis | Check clinical history for gastrointestinal, diuretic and antacid causes |
| > 7.4 (alkalosis) | < 40 mm Hg | Respiratory alkalosis | Check clinical history for hyperventilation syndrome, drug and mechanical ventilator causes |
ROME: Respiratory Opposite, Metabolic Equal.
Opposite, pH down pH below 7.4, carbon dioxide above 40: respiratory acidosisEqual, pH down both down: metabolic acidosis being compensatedEqual, pH up both up: metabolic alkalosis being compensatedOpposite, pH up pH above 7.4, carbon dioxide below 40: respiratory alkalosis
Where it breaks: ROME is an outside memory aid, not on the slide. The chart splits at the midpoints 7.4 and 40, not the normal ranges,; check the compensation with Winter’s formula and the compensation table.
| State | Potassium (slide 9) | Hemoglobin and oxygen (slides 10–11) |
|---|---|---|
| Acidosis | Hydrogen ions shift extracellular → intracellular; potassium shifts intracellular → extracellular → hyperkalemia | Decreased affinity of hemoglobin for oxygen → increased oxygen delivery to tissues; curve shifts right |
| Alkalosis | Hydrogen ions shift intracellular → extracellular; potassium shifts extracellular → intracellular → hypokalemia | Increased affinity of hemoglobin for oxygen → decreased oxygen delivery to tissues; curve shifts left |
| Slide 11 picture, shift to the right: (1) increased hydrogen ions, (2) increased carbon dioxide, (3) increased temperature, (4) increased BPG (bisphosphoglycerate). | ||
Acid pushes potassium Out and oxygen Off (Right = Release). Alkali pulls potassium In and Locks oxygen on (Left = Locked).
Acidosis → potassium out hyperkalemiaAlkalosis → potassium in hypokalemiaRight = Release acidosis: more oxygen to tissuesLeft = Locked alkalosis: less oxygen to tissuesRight-shifters hydrogen ions, carbon dioxide, temperature, bisphosphoglycerate: all increased
Where it breaks: Hydrogen and potassium always swap places: wherever hydrogen goes, potassium leaves.
| Triad feature (slide 27) |
|---|
| Obesity |
| Sleep disordered breathing |
| Chronic hypercapnia |
| Slide 27 lists it among the causes of chronic respiratory acidosis (with lung disease and neuromuscular disorders). |
Heavy, snoring, holding carbon dioxide.
Heavy obesitySnoring sleep disordered breathingHolding carbon dioxide chronic hypercapnia
Where it breaks: “Snoring” stands for the slide’s broader “sleep disordered breathing”.
| Component | Intermittent | Mild persistent | Moderate persistent | Severe persistent |
|---|---|---|---|---|
| Symptoms | ≤ 2 days/week | > 2 days/week but not daily | Daily | Throughout the day |
| Nighttime awakenings | ≤ 2×/month | 3–4×/month | > 1×/week but not nightly | Often 7×/week |
| Short-acting beta-2 agonist use for symptom control (not prevention of exercise-induced bronchospasm) | ≤ 2 days/week | > 2 days/week but not daily, and not more than 1× on any day | Daily | Several times per day |
| Interference with normal activity | None | Minor limitation | Some limitation | Extremely limited |
| Lung function: FEV1 (forced expiratory volume in 1 second) and its ratio to FVC (forced vital capacity) | Normal FEV1 between exacerbations; FEV1 > 80% predicted; ratio normal | FEV1 > 80% predicted; ratio normal | FEV1 > 60% but < 80% predicted; ratio reduced 5% | FEV1 < 60% predicted; ratio reduced > 5% |
| Risk: exacerbations requiring oral systemic corticosteroids | 0–1/year | ≥ 2/year | ≥ 2/year | ≥ 2/year |
| Slide 62 notes: severity is set by both impairment and risk; impairment is assessed by the patient’s recall of the previous 2–4 weeks and spirometry; assign severity to the most severe category in which any feature occurs. Patients with ≥ 2 exacerbations requiring oral systemic corticosteroids in the past year may be considered the same as persistent asthma, even without matching impairment. | ||||
| The slide’s normal-ratio-by-age column and its treatment row are left out: the recording put them out of scope. | ||||
Intermittent plays the rule of twos; then symptoms go not-daily, daily, all day, and FEV1 drops past 80 and 60.
Symptoms ≤ 2 days → not daily → daily → all dayNights ≤ 2/month → 3–4/month → weekly, not nightly → often nightlyRescue inhaler ≤ 2 days → not daily → daily → several times a dayActivity none → minor → some → extreme limitationFEV1 > 80 (intermittent and mild) → 60–80 → < 60Steroid bursts 0–1/year intermittent; ≥ 2/year persistent
Where it breaks: Mild and intermittent share the same FEV1 (above 80% with a normal ratio): tell them apart by symptoms, nights and rescue use. Nights break the pattern too: intermittent counts per month, moderate per week.
| Zone | Signs | Peak flow (slide 88) | Action |
|---|---|---|---|
| Green: “Doing well” / Go | Slide 88: no cough, wheeze, chest tightness, or shortness of breath during the day or night; can do usual activities. Slide 89 (all of these): breathing is good; no cough or wheeze; sleep through the night; can work and play | ≥ 80% of my best peak flow | Take long-term control medicines each day (include an anti-inflammatory); slide 89: use preventive medicine |
| Yellow: “Asthma is getting worse” / Caution | Slide 88: cough, wheeze, chest tightness, or shortness of breath; or waking at night due to asthma; or can do some, but not all, usual activities. Slide 89 (any of these): first signs of a cold; exposure to known trigger; cough; mild wheeze; tight chest; coughing at night | 50–79% | Add quick-relief medicine (short-acting beta-2 agonist) and keep taking green zone medicine; slide 89: call your primary care provider |
| Red: “Medical alert!” / Danger | Slide 88: very short of breath; or quick-relief medicines have not helped; or cannot do usual activities; or symptoms are same or get worse after 24 hours in yellow zone. Slide 89 (getting worse fast): medicine is not helping; breathing is hard and fast; nose opens wide; ribs show; can’t talk well | < 50% | Take quick-relief medicine and oral steroid, then call your doctor now; slide 89: get help from a doctor |
| Danger signs (slide 88) | Trouble walking and talking due to shortness of breath; lips or fingernails are blue | — | Take 4 or 6 puffs of quick-relief medicine and go to the hospital or call an ambulance now |
Traffic light at 80 and 50: green 80 and up, yellow 50–79, red under 50.
Green ≥ 80%, no symptoms day or night, usual activities: daily controllerYellow 50–79%, symptoms or night waking or some activities: add quick-reliefRed < 50%, very short of breath, quick-relief failing, or 24 hours in yellow without improvingDanger signs cannot walk and talk; blue lips or nails
Where it breaks: Slide 89’s traffic light has no percentages, and the danger signs are judged by sight, not by peak flow. Yellow that lasts 24 hours without improving becomes red.
| Test | Cut-off | Meaning |
|---|---|---|
| Spirometry before and after a bronchodilator (slide 53) | FEV1 (forced expiratory volume in 1 second) improves ≥ 12% | Supports asthma (before the bronchodilator: reduced FEV1 and reduced ratio) |
| Bronchial provocation: methacholine or histamine (slide 58) | Not recommended if FEV1 < 65% predicted | Useful if spirometry is not diagnostic; exercise challenge if exercise-induced bronchospasm is suspected |
| Peak expiratory flow at home (slide 60) | 20% change morning vs afternoon, or 20% change day to day | Poor control (measured in the morning before and the afternoon after the bronchodilator) |
| Exercise-induced bronchospasm (slide 94) | Begins during or within 3 minutes after exercise; peaks in 10–15 minutes; resolves by 60 minutes | Common in children and adolescents |
| Slide 53 reads “FEV1 ≥12% or ≥ 10% improvement in predicted FEV1”; questions use the 12%. | ||
Up 12 to diagnose, 65 is the floor for provoking, a 20% swing means poor control, and exercise runs on a 3-15-60 clock.
12 bronchodilator response that supports asthma65 no provocation test below 65% predicted20 peak flow swing (morning to afternoon or day to day) = poor control3-15-60 exercise bronchospasm: starts by 3, peaks 10–15, gone by 60 minutes
Where it breaks: The 15 in the clock is the top of a 10–15 minute peak, not a single time.
| Feature | Extrinsic (slide 35) | Intrinsic (slides 34–35) |
|---|---|---|
| Trigger | Triggered by allergen exposure | Not triggered by allergen exposure |
| How common | Most common form of asthma | Minority (~10%) |
| Atopy and tests | — | Not atopic; negative skin allergy tests and normal serum IgE (immunoglobulin E) |
| Onset and course | — | Later onset (adulthood); usually more severe, persistent |
| Associations | — | Nasal polyps common; may be aspirin sensitive |
| Pathology | Same in both | Same in both |
Intrinsic is the Late Adult with Polyps and Aspirin and clean allergy tests (LAPA).
Allergen extrinsic is triggered by it, intrinsic is notMost common extrinsic; intrinsic only about 10%Clean tests intrinsic: negative skin tests, normal IgEL, A Late onset in Adulthood, more severe and persistentP, A Polyps, Aspirin sensitivitySame pathology does not differ
Where it breaks: The slides describe intrinsic in detail and extrinsic only by its trigger and frequency; the dashes are blanks on the slides, not negatives.
| Risk factor (slide 14) |
|---|
| Poorly controlled asthma: frequent bronchodilator use |
| No inhaled corticosteroids |
| Poor compliance with inhaled corticosteroids |
| Previous admissions for near-fatal attacks |
Too much rescue, too little steroid (none or skipped), and a near-death before.
Too much rescue frequent bronchodilator useNone no inhaled corticosteroidSkipped poor compliance with the inhaled corticosteroidNear-death before previous admission for a near-fatal attack
Where it breaks: Two of the four are the same drug: the inhaled corticosteroid either never prescribed or not taken.
| Triad member (slide 25) |
|---|
| Allergic rhinitis |
| Asthma |
| Atopic dermatitis |
| Slide 25: atopy = genetic disposition for developing allergic reaction, with elevated IgE (immunoglobulin E) on exposure to allergen; non-atopic individuals have a low risk of asthma, and not all atopic individuals develop it. |
Sneeze, wheeze, itch.
Sneeze allergic rhinitisWheeze asthmaItch atopic dermatitis
Where it breaks: Do not confuse it with the intrinsic picture (nasal polyps, aspirin sensitivity), which is not atopic.
| Group (slide 93) | Drugs |
|---|---|
| Avoid: non-selective NSAIDs (nonsteroidal anti-inflammatory drugs) | Diclofenac · ibuprofen · naproxen · indomethacin |
| May use: selective NSAIDs | Celecoxib · meloxicam |
Avoid the DINI; you Can Manage with the selective two.
D diclofenacI ibuprofenN naproxenI indomethacinC celecoxibM meloxicam
Where it breaks: The slide lists brand names beside the selective drugs; only the generic names are used here.
| Finding | Meaning (slide wording) |
|---|---|
| Post-bronchodilator FEV1/FVC (forced expiratory volume in 1 second / forced vital capacity) < 0.70 | Confirms the diagnosis (slide 26); spirometry before and after a bronchodilator (albuterol) is required |
| FEV1 improvement of < 12% after bronchodilator | Irreversible airway obstruction: more likely chronic obstructive pulmonary disease than asthma (slide 26) |
| Is the FEV1 low? Yes | The pattern is obstruction (slide 27) |
| Obstructed and FVC low | Possible mixed disorder, confirmed with TLC (total lung capacity) |
| FEV1/FVC normal and FVC low | Possible restriction, confirm with TLC |
| Chronic bronchitis without airflow obstruction | Is NOT chronic obstructive pulmonary disease (slide 6) |
| Slide 27 opens with “Is the FEV1 low? If yes, the pattern is obstruction”; slide 26 and the grading table confirm the disease by the ratio below 0.70. Both are on the slides. | |
Seventy and twelve: under 0.70 confirms it, under 12% back means it stays.
< 0.70 ratio after a bronchodilator: confirms< 12% little bronchodilator response: irreversibleLow FEV1 obstructionLow FEV1 + low FVC maybe mixed: check total lung capacityNormal ratio + low FVC maybe restriction: check total lung capacityNo obstruction chronic bronchitis alone is not the disease
Where it breaks: Total lung capacity, not spirometry, settles both “possible” patterns.
| Feature (slide 14) | Chronic bronchitis subtype | Emphysema subtype |
|---|---|---|
| Definition | Clinical: chronic productive cough | Pathologic: alveolar wall destruction and airspace enlargement |
| Primary site | Large and small airways (mucus gland hyperplasia, goblet cells, wall thickening) | Respiratory bronchioles and alveoli |
| Patterns | Mucus hypersecretion | Centrilobular (smoking, upper lobes) vs panlobular (alpha-1 antitrypsin deficiency, lower lobes) |
| Mechanism of obstruction | Airway narrowing and mucus plugging | Loss of elastic recoil, which causes airways to collapse on expiration |
| Classic descriptor | “Blue bloater” | “Pink puffer” |
| Typical exam | Cough, sputum, rhonchi, possible cyanosis and edema (cor pulmonale) | Thin, pursed-lip breathing, barrel chest, distant breath sounds, hyperresonance |
| Gas exchange | Earlier hypoxemia and hypercapnia | Relatively preserved until late |
| DLCO (diffusing capacity of the lung for carbon monoxide) | Normal or near normal | Reduced |
| Imaging | Bronchial wall thickening | Hyperinflation, flat diaphragms, bullae; computed tomography shows emphysema |
| Slide 6: chronic bronchitis = chronic cough and sputum production, typically for at least 3 months per year for 2 consecutive years; emphysema = an anatomic, pathologic definition. | ||
Blue Bloater = Bronchitis (big airways, Blocked by mucus); Pink Puffer = Parenchyma (alveoli Popped, recoil lost).
3 × 2 bronchitis: 3 months a year, 2 years runningBronchitis airways, mucus plugging, early low oxygen and high carbon dioxide, normal diffusing capacityEmphysema alveoli, lost recoil, gas exchange kept until late, reduced diffusing capacityUpper vs lower centrilobular = smoking, upper; panlobular = alpha-1 antitrypsin deficiency, lowerExam bloater: sputum, cyanosis, edema; puffer: thin, pursed lips, barrel chest
Where it breaks: Diffusing capacity is the cleanest single split: normal in bronchitis, reduced in emphysema.
| Item | Slide wording |
|---|---|
| Suggestive subsets (slide 19) | Emphysema in a young individual (≤ 45 years) · emphysema in a nonsmoker or minimal smoker · emphysema predominantly basilar on chest x-ray · family history of emphysema |
| Pattern (slides 14, 19) | Panlobular, lower lobes (slide 14); typically panacinar rather than the centracinar emphysema seen in smokers (slide 19) |
| Diagnostic (slide 30) | Alpha-1 antitrypsin < 11 micromol/L with a severe deficient genotype |
| Slide 12: a genetic risk found in nonsmokers, about 3 or 4 cases per 10,000. | |
| The age line differs by slide: slide 19 says 45 or younger, slide 10 says under 45. No question sits on exactly 45. | |
The “too” rule: too young, too clean, too low, too familial; and under 11 proves it.
Too young 45 or youngerToo clean nonsmoker or minimal smokerToo low basilar (lower-lobe, panlobular) emphysemaToo familial family history of emphysema< 11 micromol/L with a severe deficient genotype = diagnostic
Where it breaks: The level alone is not enough on slide 30: it needs the severe deficient genotype too.
| GOLD (Global Initiative for Chronic Obstructive Lung Disease) grade | Severity | Post-bronchodilator FEV1 (forced expiratory volume in 1 second), % predicted |
|---|---|---|
| GOLD 1 | Mild | ≥ 80% |
| GOLD 2 | Moderate | 50% ≤ FEV1 < 80% (slide 35: 50–79) |
| GOLD 3 | Severe | 30% ≤ FEV1 < 50% (slide 35: 30–49) |
| GOLD 4 | Very severe | < 30% |
| Slide 34: grades apply to patients with FEV1/FVC (forced vital capacity) < 0.7, based on the post-bronchodilator FEV1. | ||
The grades fall at 80, 50 and 30: mild, moderate, severe, very severe.
1 mild, 80% and above2 moderate, 50–79%3 severe, 30–49%4 very severe, below 30%
Where it breaks: The steps are uneven (30 points, then 20), and the group is assigned from symptoms and exacerbations, not from the grade (slide 36 only says which grades are typical).
| Grade | Statement (tick one box only) |
|---|---|
| 0 | I only get breathless with strenuous exercise |
| 1 | I get short of breath when hurrying on the level or walking up a slight hill |
| 2 | I walk slower than people of the same age on the level because of breathlessness, or I have to stop for breath when walking on my own pace on the level |
| 3 | I stop for breath after walking about 100 meters or after a few minutes on the level |
| 4 | I am too breathless to leave the house or I am breathless when dressing or undressing |
| In the group assessment (slides 35–37), grade ≥ 2 = more symptoms; 0–1 = fewer. | |
The walk shrinks each grade: Exercise, Hill, Peers, 100 meters, House.
Exercise 0: only strenuous exerciseHill 1: hurrying on the level or a slight hillPeers 2: slower than people my age, or stop at my own pace100 meters 3: stop after about 100 meters or a few minutesHouse 4: cannot leave the house, or breathless dressing
Where it breaks: Grade 2 has two ways in (slower than peers, or stopping at one’s own pace); it is also where “more symptoms” begins.
| Item: 0 end | Item: 5 end |
|---|---|
| I never cough | I cough all the time |
| I have no phlegm (mucus) in my chest at all | My chest is completely full of phlegm (mucus) |
| My chest does not feel tight at all | My chest feels very tight |
| When I walk up a hill or one flight of stairs I am not breathless | When I walk up a hill or one flight of stairs I am very breathless |
| I am not limited doing any activities at home | I am very limited doing activities at home |
| I am confident leaving my home despite my lung condition | I am not at all confident leaving my home because of my lung condition |
| I sleep soundly | I don’t sleep soundly because of my lung condition |
| I have lots of energy | I have no energy at all |
| Each item is scored 0–5 and summed. In the group assessment, total ≥ 10 = more symptoms, < 10 = fewer (slides 35–37). The slide 29 algorithm writes “CAT score >10”, and the slide 35 GOLD 2026 picture spells it “CAAT”. | |
Three chest, five life: cough, phlegm, tightness; then stairs, home, going out, sleep, energy. Ten or more = more symptoms.
Cough item 1Phlegm item 2Tightness item 3Stairs hill or one flightHome activities at homeGoing out confidence leaving homeSleep sleeps soundlyEnergy lots or none
Where it breaks: Only the cut-off of 10 is used for grouping; the slides give no other score bands.
| Group | Exacerbation risk | Symptoms |
|---|---|---|
| A: low risk, less symptoms | 0 or 1 exacerbation per year, no hospitalization | CAT < 10 or mMRC 0–1 |
| B: low risk, more symptoms | 0 or 1 exacerbation per year, no hospitalization | CAT ≥ 10 or mMRC ≥ 2 |
| C: high risk, less symptoms | ≥ 2 exacerbations per year or ≥ 1 hospitalization | CAT < 10 or mMRC 0–1 |
| D: high risk, more symptoms | ≥ 2 exacerbations per year or ≥ 1 hospitalization | CAT ≥ 10 or mMRC ≥ 2 |
| Slide 36 adds the airflow grade each group “typically” has; that line is never used to assign a group: groups come from symptoms and exacerbation history. CAT = chronic obstructive pulmonary disease Assessment Test; mMRC = modified Medical Research Council dyspnea grade. | ||
“S × R = Group” (slide 41’s own aid): Symptoms across, Risk up.
A low symptoms, low riskB high symptoms, low riskC low symptoms, high riskD high symptoms, high risk
Where it breaks: The letters run like a grid read bottom row first (A, B), then the top row (C, D); 2023/2026 merges C and D into E.
| Group | Exacerbation history (per year) | Symptoms | Initial treatment (slide 37 Figure 4.2, slide 40) |
|---|---|---|---|
| A | 0 or 1 moderate exacerbations (not leading to hospital admission) | mMRC 0–1, CAT < 10 | A bronchodilator (short- or long-acting) |
| B | 0 or 1 moderate exacerbations (not leading to hospital admission) | mMRC ≥ 2, CAT ≥ 10 | LABA + LAMA (long-acting beta-2 agonist + long-acting muscarinic antagonist: dual bronchodilators) |
| E | ≥ 2 moderate exacerbations or ≥ 1 leading to hospitalization (Figure 4.2, slide 40) | Any | LABA + LAMA; consider LABA + LAMA + ICS (inhaled corticosteroid) if blood eosinophils ≥ 300 |
| Slide conflict: the GOLD 2026 picture on slide 35 and the second picture on slide 37 define the high-risk (E) row as “One or more (≥ 1) moderate or severe exacerbations in the previous year” and A/B as “Zero (0)”; slide 36, slide 37’s Figure 4.2 and slide 40 say ≥ 2 moderate or ≥ 1 leading to hospitalization. Not resolved here. | |||
| Figure 4.2: single inhaler therapy may be more convenient and effective than multiple inhalers; the table is for initial treatment of patients naive to maintenance therapy (slide 37). The slide 35 picture spells the test “CAAT”. | |||
A = A bronchodilator; B = Both bronchodilators; E = Exacerbator: both, plus a steroid if Eosinophils are 300 or more.
A few symptoms, low risk: one bronchodilatorB many symptoms, low risk: long-acting beta-2 agonist + long-acting muscarinic antagonistE high risk at any symptom level: the same pair ± inhaled corticosteroid300 blood eosinophil count that adds the inhaled corticosteroid
Where it breaks: Symptoms split only the low-risk row; E ignores them. Where the high-risk line sits (one exacerbation, or two or one hospitalization) differs between the slides: see the note.
| Patient group (Table 4.9) | Essential | Recommended | Depending on local guidelines |
|---|---|---|---|
| A | Smoking cessation (can include pharmacological treatment) | Physical activity | Flu, pneumococcal, pertussis, COVID-19 and shingles vaccinations |
| B and E | Smoking cessation (can include pharmacological treatment); pulmonary rehabilitation | Physical activity | Flu, pneumococcal, pertussis, COVID-19 and shingles vaccinations |
| Slide 48: every patient should get a yearly influenza shot (reduces hospitalizations and death); pneumococcal vaccine at age 65, earlier with severe disease (FEV1 (forced expiratory volume in 1 second) < 40%) or cardiac comorbidities. Vaccine product names are not used. | |||
Everyone quits and moves; B and E also go to Rehab.
Quits smoking cessation: essential for allMoves physical activity: recommended for allRehab pulmonary rehabilitation: essential in B and E onlyFive shots flu, pneumococcal, pertussis, COVID-19, shingles per local guidelines
Where it breaks: The two rows differ by one cell only: pulmonary rehabilitation.
| Variable | 0 points | 1 point | 2 points | 3 points |
|---|---|---|---|---|
| FEV1 (forced expiratory volume in 1 second), % of predicted | ≥ 65 | 50–64 | 36–49 | ≤ 35 |
| 6-minute walk distance (meters) | ≥ 350 | “250-249” (see note) | 150–249 | ≤ 149 |
| mMRC (modified Medical Research Council) dyspnea scale | mMRC 0–1 | mMRC 2 | mMRC 3 | mMRC 4 |
| Body-mass index | > 21 | ≤ 21 | — | — |
| Slide 52 prints the 1-point walk band as “250-249”; between its neighbors it can only be 250–349. Questions avoid that band. | ||||
BODE = Body-mass index, Obstruction, Dyspnea, Exercise. Cut-offs: FEV1 65, 50, 35; walk 350, 250, 150; body-mass index 21.
B body-mass index: above 21 = 0, 21 or less = 1O obstruction (FEV1): 65 / 50–64 / 36–49 / 35 or lessD dyspnea (mMRC): 0–1, 2, 3, 4 → 0, 1, 2, 3 pointsE exercise (6-minute walk): 350 / 250 / 150 / 149 or less
Where it breaks: Body-mass index scores only 0 or 1, so the total runs 0–10. The dyspnea row is the mMRC grade minus one (0–1 both score 0).
| BODE index score (total points) | Estimated 4-year survival |
|---|---|
| 0–2 | 80% |
| 3–4 | 67% |
| 5–6 | 57% |
| 7–10 | 18% |
80, 67, 57, then off the cliff at 7: 18%.
0–2 80%3–4 67%5–6 57%7–10 18%
Where it breaks: The first three bands drop about 10 points each; the last band is wider (7–10) and the drop is far steeper.
| Situation (slide 64) | Oxygen saturation | Decision |
|---|---|---|
| Severe resting desaturation | ≤ 88% at rest | Qualifies for LTOT (long-term oxygen therapy) > 15 h/day; cor pulmonale absent: titrate to goal > 89%; present: > 90%–92% |
| Moderate resting desaturation | 89%–93% at rest | No indication for long-term oxygen |
| Severe exertional desaturation (mobile, exertional symptoms: exercise test) | ≤ 88% with exertion | Qualifies for long-term oxygen during exertion |
| Moderate exertional desaturation | 89%–93% on exertion | No indication for long-term oxygen |
| Nocturnal desaturation | ≤ 88% at night only | Evaluate for OSA (obstructive sleep apnea) and screen for other etiologies |
| Slide 63: treat if arterial oxygen < 55 mm Hg or saturation < 88%; slide 64 uses ≤ 88%. Slide 63 also says societies disagree on the saturation target (88–92% vs 90% vs at least 90%); no target is tested. | ||
| Slide 20: may need oxygen acutely if saturation is below 95% on room air, but a baseline below 88% requires oxygen chronically. | ||
Eighty-eight earns oxygen; 89 to 93 gets none; night-only dips mean look for sleep apnea.
≤ 88 at rest long-term oxygen more than 15 hours a day89–93 no long-term oxygen, at rest or on exertion≤ 88 on exertion oxygen during exertion≤ 88 at night only evaluate for obstructive sleep apneaGoal above 89%; 90–92% if cor pulmonale
Where it breaks: Exactly 88% qualifies on slide 64 (≤ 88) but not by slide 63’s wording (< 88).
| Level | Criteria (slide wording) |
|---|---|
| Exacerbation (slide 56) | Acute worsening of dyspnea, cough, or sputum over 14 days or less; > 80% can be managed outpatient |
| Admission (slide 57) | Marked symptoms despite acute management (moving the patient into a severe category) · requires noninvasive ventilatory support (BiPAP, bilevel positive airway pressure) · new physical signs (edema, arrhythmia, unable to control secretions) · significant comorbidities with an exacerbation · age · lack of home or outpatient resources |
| Intensive care unit admission (slide 57) | Hemodynamically unstable, major infection, or requiring invasive ventilatory support: sepsis, altered mental status, respiratory failure, respiratory acidosis, low arterial oxygen (< 40 mm Hg or 5.3 kPa) |
| Slide 57 writes the oxygen value as “PAO2”. | |
Admit when My Breathing Needs Care At Home-less; intensive care when Unstable, Infected, Intubated.
14 an exacerbation runs 14 days or less; over 80% stay outpatientM, B, N Marked symptoms, BiPAP needed, New signsC, A, H Comorbidities, Age, Home resources lackingU, I, I Unstable hemodynamics, major Infection, Invasive ventilation40 arterial oxygen below 40 mm Hg = intensive care
Where it breaks: Noninvasive support is an admission criterion; invasive support moves the patient to intensive care.
| Situation (slide 59) | Choice |
|---|---|
| When to give | Shortness of breath with increased sputum volume and purulence over baseline |
| Oral, uncomplicated (Haemophilus influenzae, strep, gram-positive) | Doxycycline, macrolides, trimethoprim-sulfamethoxazole, or amoxicillin-clavulanate |
| Resistance | Respiratory fluoroquinolones: levofloxacin or moxifloxacin |
| Pseudomonal concern | Levofloxacin |
| Intravenous antibiotics | Systemic or severe respiratory infection affecting oxygen saturation and other vitals (elevated lactate, white blood cells) · ventilation requiring support (noninvasive or invasive) |
| The slide names trimethoprim-sulfamethoxazole and amoxicillin-clavulanate by brand. Slide 59 also: some patients are put on long-term azithromycin or erythromycin (rare; raises resistance and side effects). Order on the slide: bronchodilators, oral corticosteroids, antibiotics, hospitalization. | |
Breathless + more + pus = antibiotics. Oral: Doxycycline, Macrolide, Trimethoprim-sulfamethoxazole, Amoxicillin-clavulanate (“Do More Than Amoxicillin”); resistance = a respiratory fluoroquinolone, Levofloxacin for pseudomonas.
More + pus increased sputum volume and purulence with dyspneaD, M, T, A the four oral first choicesResistance levofloxacin or moxifloxacinPseudomonas levofloxacinIntravenous sepsis-type vitals or labs, or ventilation support
Where it breaks: Levofloxacin appears twice: as a resistance choice and as the pseudomonal choice; moxifloxacin is only the former.
| Criterion (Table 1) |
|---|
| Able to use long-acting bronchodilators, either beta-2 agonists and anticholinergics with or without inhaled corticosteroids |
| Inhaled short-acting beta-2 agonist therapy is required no more frequently than every 4 hours |
| Patient, if previously ambulatory, is able to walk across room |
| Patient is able to eat and sleep without frequent awakening by dyspnea |
| Patient has been clinically stable for 12–24 hours |
| Patient (or home caregiver) fully understands correct use of medications |
| Follow-up and home care arrangements have been completed (visiting nurse, oxygen delivery, meal provisions) |
| Patient, family, and physician are confident that the patient can manage successfully at home |
| Consider pulmonary rehabilitation |
2 drugs, 3 body checks, 4 plans.
Drug 1 on long-acting bronchodilatorsDrug 2 rescue inhaler no more than every 4 hoursBody 1 walks across the roomBody 2 eats and sleeps without waking breathlessBody 3 stable 12–24 hoursPlan 1 understands the medicinesPlan 2 follow-up and home care arrangedPlan 3 everyone confident at homePlan 4 consider pulmonary rehabilitation
Where it breaks: “Walk across the room” applies only if the patient walked before admission.
| Reason (slide 54) |
|---|
| Diagnostic uncertainty |
| Early age of onset/suspected alpha-1 antitrypsin deficiency |
| Frequent exacerbations despite optimal therapy |
| Long-term oxygen therapy |
| Evaluation for noninvasive ventilation (continuous or bilevel positive airway pressure) |
| Possible surgical need |
| Symptoms out of proportion to pulmonary function tests |
| Slide 54, others: pulmonary rehabilitation, smoking cessation programs, pharmacist/respiratory therapist for inhaler review, palliative care, behavioral health. |
Doctors You Find Often Need Surgical Skills.
D Diagnostic uncertaintyY Young onset / suspected alpha-1 antitrypsin deficiencyF Frequent exacerbations despite optimal therapyO long-term Oxygen therapyN Noninvasive ventilation evaluationS Surgical need possibleS Symptoms out of proportion to lung tests
Where it breaks: The “others” line (rehabilitation, cessation programs, pharmacist, palliative, behavioral health) is not in the aid.
| Stage | Description | Statement |
|---|---|---|
| Precontemplation | No intention to change behavior in the foreseeable future; often unaware of their problems | “I do not think that I need to change any behaviors.” |
| Contemplation | Aware that a problem exists and seriously thinking about overcoming it; no commitment to take action | “I’m concerned about my behavior, but not ready to make any changes now.” |
| Preparation | Expressed intention to take action soon; reporting small behavioral changes | “I’m ready to change my behavior now.” |
| Action | Modify their behavior for a period from 1 day to 6 months | “I’m changing my behavior now.” |
| Maintenance | Continue the change (usually > 6 months) and work to prevent relapse | “I’ve changed my behavior.” |
| Relapse | Cessation of behavioral changes; revert to old behavior. Not a stage itself: a return from action or maintenance to an earlier stage | “I’ve returned to my old behavior.” |
Pre-Contemplate, Contemplate, Prepare, Act, Maintain; 6 months is the line between Action and Maintenance.
Pre no intention, unawareContemplate aware, thinking, not committedPrepare intends soon, small changesAct changing, 1 day to 6 monthsMaintain changed, more than 6 monthsRelapse a return, not a stage
Where it breaks: Preparation already shows small changes; it is the intent to act “soon” that keeps it before Action.
| Vaccine | Who | When / how often |
|---|---|---|
| Influenza | Everyone 6 months or older without a contraindication; 65+ preferentially high-dose, adjuvanted or recombinant; pregnancy inactivated or recombinant (no live attenuated) | Every year; most adults September–October |
| COVID-19 | Adults 18+ (updated seasonal vaccine); immunocompromised from 6 months on a modified schedule | Seasonal; 65+ generally two doses about 6 months apart |
| Tdap (tetanus, diphtheria, acellular pertussis) / Td | One Tdap if no documented prior dose | Then Td or Tdap every 10 years; Tdap every pregnancy, early in weeks 27–36 |
| Pneumococcal | All adults 50+; ages 19–49 with a risk condition | PCV20 or PCV21 (20- or 21-valent conjugate) alone, or PCV15 then PPSV23 (polysaccharide) usually 1 year or more later |
| RSV (respiratory syncytial virus) | All 75+; 50–74 at increased risk; pregnancy 32–36 weeks (maternal vaccine) | One dose; not annual |
| Hib (Haemophilus influenzae type b) | Selected indications: asplenia without prior vaccination; after hematopoietic stem-cell transplant | One dose, preferably 14+ days before elective splenectomy; 3-dose series after transplant |
| Egg allergy needs no egg-free product or extra precautions (slide 6). The lecturer: vaccines “not a lot of detail on the exam”. | ||
Every adult gets the FaCT; age and risk add the PRH.
F Flu, every yearC COVID-19, seasonal (65+ generally twice)T Tdap once, then every 10 years, and every pregnancyP Pneumococcal: 50+, or 19–49 with riskR RSV: once, 75+ or 50–74 at riskH Hib: asplenia or stem-cell transplant only
Where it breaks: Influenza starts at 6 months, not in adulthood; the FaCT is “every adult” only in the sense of slide 124.
| Group | Conditions listed on slide 10 |
|---|---|
| Habits | Alcoholism · cigarette smoking |
| Holes and hardware | Cerebrospinal fluid leak · cochlear implant |
| Organs failing | Chronic heart, liver or lung disease · chronic kidney failure · nephrotic syndrome |
| Immunity broken | HIV (human immunodeficiency virus) · immunodeficiency · immunosuppression · asplenia (no spleen) · sickle cell disease and other hemoglobinopathies · solid organ transplant · cancer |
| Sugar | Diabetes mellitus |
HHOIS: two Habits, two Holes, failing Organs, broken Immunity, and Sugar.
H Habits: alcoholism, cigarette smokingH Holes and hardware: cerebrospinal fluid leak, cochlear implantO Organs: chronic heart, liver, lung disease; chronic kidney failure; nephrotic syndromeI Immunity: HIV, immunodeficiency, immunosuppression, asplenia, sickle cell and hemoglobinopathies, solid organ transplant, cancerS Sugar: diabetes mellitus
Where it breaks: The grouping is ours; the slide gives one long list, mostly alphabetical (sickle cell disease appears twice on it).
| Type | Definition (slide 25) |
|---|---|
| Community-acquired (CAP) | Acquired outside the hospital or present early in admission; prior healthcare contact does not exclude it |
| Hospital-acquired (HAP) | Develops 48 hours or more after admission; not incubating on admission |
| Ventilator-associated (VAP) | Develops more than 48 hours after endotracheal intubation |
| Aspiration pneumonia | Infection after aspiration; community or hospital |
| The healthcare-associated (HCAP) category is retired: nursing-home residence or healthcare exposure alone does not mandate broad-spectrum therapy. | |
48 is the line: 48 hours or more after the door = HAP, more than 48 after the tube = VAP.
Before 48 h / outside CAP48 h after the door (admission) HAP48 h after the tube (intubation) VAPAfter aspiration, anywhere aspiration pneumonia
| Letter | Item and cut-off (slide 31) | Points |
|---|---|---|
| C | Confusion: Abbreviated Mental Test Score 8 or less, or new disorientation to person, place or time | +1 |
| U | Urea: blood urea nitrogen above 20 mg/dL (7 mmol/L) | +1 |
| R | Respiratory rate 30 or more breaths per minute | +1 |
| B | Blood pressure: systolic below 90 or diastolic 60 or less mmHg | +1 |
| 65 | Age 65 or older | +1 |
The name is the list: C-U-R-B-65, one point each, 0 to 5.
C ConfusionU Urea above 20 mg/dLR Respiratory rate 30 or moreB Blood pressure: systolic below 90 or diastolic 60 or less65 Age 65 or older
Where it breaks: Urea above 20 is strictly greater; respiratory rate 30 counts (30 or more).
| Total | Severity (risk of death) | Where (slide 29 algorithm) |
|---|---|---|
| 0–1 | Low (under 3%) | Home with antibiotics, unless other reasons to admit (unstable comorbidity, social) |
| 2 | Moderate (9%) | Hospital: supportive care, microbiology, antibiotics |
| 3–5 | High (15–40%) | Hospital, urgent senior review; consider critical care, especially at 4 or 5 |
| Slide 31: the Pneumonia Severity Index is preferred for admission support; CURB-65 complements, but does not replace, clinical judgment. Aim: diagnosis and antibiotics within 4 hours (slide 29). | ||
0–1 go home, 2 come in, 3 or more call for help (4–5 think intensive care).
0–1 home2 hospital3–5 hospital plus senior review; intensive care at 4–5
| Finding (slide 30 calculator) | Points |
|---|---|
| Female sex | −10 |
| Age | 1 per year |
| Nursing home resident | +10 |
| Neoplastic disease | +30 |
| Liver disease | +20 |
| Congestive heart failure | +10 |
| Cerebrovascular disease | +10 |
| Renal disease | +10 |
| Altered mental status | +20 |
| Respiratory rate 30/minute or more | +20 |
| Systolic blood pressure below 90 mmHg | +20 |
| Temperature below 35 °C or 40 °C or more | +15 |
| Pulse 125/minute or more | +10 |
| Arterial pH below 7.35 | +30 |
| Classes: I = 0.1% mortality · II = 51–70 points, 0.6% · III = 71–90, 0.9% · IV = 91–130, 9.3% · V = 131–395, 27.0% | |
| The slide’s calculator picture is cropped after arterial pH, and Class I has no point range on the slide; use the class table only with a given total. | |
Thirties are the killers (cancer, acid); twenties are the brain, lungs, pressure and liver; tens are the heart, stroke, kidney, home and pulse; women start 10 lower.
30 neoplastic disease, arterial pH below 7.3520 liver disease, altered mental status, respiratory rate 30+, systolic below 9015 temperature below 35 or 40+10 heart failure, cerebrovascular disease, renal disease, nursing home, pulse 125+−10 female sex+1/year ageClasses II 51–70, III 71–90, IV 91–130, V 131+
Where it breaks: Covers only the items visible on the slide; the full calculator continues past the crop.
| Nonsevere | Severe | |
|---|---|---|
| Severity signal | No major criterion and fewer than three minor criteria | Vasopressor-dependent shock, mechanical ventilation, or at least three minor criteria |
| Place of care | Pneumonia Severity Index plus judgment: outpatient or general ward | Urgent intensive-care-level assessment and support |
| Treatment | Outpatient or nonsevere inpatient regimen; resistant-pathogen coverage only for validated risk | Beta-lactam combination regimen; cultures; resistant coverage only when risk supports it |
| Duration | Fewer than 5 days possible once stable, minimum 3 | At least 5 days and until clinically stable |
| The minor criteria are not listed anywhere on the slides; only the two major criteria are. | ||
Severe = Squeezers or a Snorkel (or three minors); severe gets 5, nonsevere at least 3.
Squeezers vasopressor-dependent shockSnorkel mechanical ventilationThree minors at least three minor criteria3 and 5 minimum days: nonsevere 3, severe 5
| Adult outpatient | Empiric treatment |
|---|---|
| No comorbidities, no MRSA (methicillin-resistant Staphylococcus aureus) or Pseudomonas risk | Amoxicillin OR doxycycline; macrolide monotherapy only if local pneumococcal resistance is below 25% |
| Comorbidities: chronic heart, lung, liver or renal disease, diabetes, alcoholism, malignancy, asplenia (immunocompromised: separate assessment) | Amoxicillin/clavulanate, cefpodoxime or cefuroxime PLUS azithromycin or doxycycline, OR a respiratory fluoroquinolone (levofloxacin or moxifloxacin); review allergy, QT, interactions, fluoroquinolone risks |
| Doses on the slide are left out here. | |
Healthy gets A or D; sick gets a beta-lactam with a Partner, or a Fluoroquinolone Flying solo.
A or D amoxicillin or doxycycline (macrolide alone only if resistance below 25%)Beta-lactam + Partner amoxicillin/clavulanate, cefpodoxime or cefuroxime plus azithromycin or doxycyclineFlying solo levofloxacin or moxifloxacin alone
| Adult inpatient | Empiric treatment |
|---|---|
| Nonsevere, no MRSA (methicillin-resistant Staphylococcus aureus) or Pseudomonas risk | Beta-lactam (for example ceftriaxone or ampicillin/sulbactam) plus a macrolide, OR respiratory fluoroquinolone monotherapy; beta-lactam plus doxycycline when macrolides and fluoroquinolones are unsuitable |
| Severe (intensive care evaluation: vasopressor-dependent shock or respiratory failure needing ventilation) | Beta-lactam PLUS azithromycin or a respiratory fluoroquinolone; add MRSA or Pseudomonas coverage only for validated risks; cultures and de-escalation; severe beta-lactam allergy: review with pharmacy or infectious disease |
Ward: BL + M or F alone (D if neither fits). Intensive care: BL + A or F, the beta-lactam always in.
BL + M beta-lactam plus macrolide (nonsevere)F alone respiratory fluoroquinolone monotherapy (nonsevere only)BL + D beta-lactam plus doxycycline when macrolide and fluoroquinolone are unsuitableBL + A or F severe: beta-lactam plus azithromycin or a fluoroquinolone
| Clinical situation | Treatment approach |
|---|---|
| No major resistance or high mortality risk | Antipseudomonal agent with MSSA (methicillin-sensitive S. aureus) coverage by the local antibiogram: piperacillin/tazobactam or cefepime |
| MRSA (methicillin-resistant S. aureus) risk, resistance risk or high mortality risk | Add vancomycin or linezolid for it; a second antipseudomonal class for selected high-risk patients; cultures, daily reassessment, de-escalation |
| Duration | Usually 7 days if response is adequate |
| Moxifloxacin and ertapenem are not reliable Pseudomonas options (slide 40). Early or late timing alone does not select the regimen (slide 39). | |
Pip or Cef for Pseudomonas; V or L for MRSA; 7 days.
Pip or Cef piperacillin/tazobactam or cefepime (antipseudomonal backbone)V or L vancomycin or linezolid when methicillin-resistant S. aureus coverage is indicatedSecond class a second antipseudomonal class for selected high-risk patients7 usual duration in days
| Pattern | Signs | Usual cause |
|---|---|---|
| Lobar | Homogeneous consolidation, silhouette sign, air bronchogram, sharply marginated fissure | Streptococcus pneumoniae |
| Bronchopneumonia | Poorly defined heterogeneous patchy infiltrates scattered through the lung; air bronchogram | Staphylococcus aureus: multilobar, cavitation, pneumatoceles, abscess |
| Interstitial | Bilateral, diffuse fine reticular opacity | Pneumocystis jirovecii pneumonia |
| Aspiration | Airspace opacity in a lobar or segmental distribution; gravity-dependent predilection | Stroke, seizure |
| The lecturer: the example films will not be shown on the exam as “what is it.” | ||
Lobar Loves pneumococcus; Broncho Burrows (staph cavities); Interstitial = Immunocompromised (Pneumocystis); Aspiration falls Downhill after a stroke or seizure.
Lobar Streptococcus pneumoniaeBroncho Staphylococcus aureusInterstitial PneumocystisAspiration stroke, seizure; gravity-dependent
| Stage | What happens |
|---|---|
| 1 Congestion | Exudate congests the alveoli and capillaries; the first 24 hours (later for atypicals) |
| 2 Red hepatization | Fibrin and red cells fill the area; no airflow; hyperemia |
| 3 Gray hepatization | Area becomes avascular; leukocytes attack |
| 4 Resolution | Macrophages clean up; airflow returns |
| The lecturer: “These aren’t cold, hard, fast rules.” Learn the order; the slide’s day ranges are not tested. | |
Cars Run Gray to Rust: Congestion, Red, Gray, Resolution.
C congestionR red hepatizationG gray hepatizationR resolution
| Pneumonitis | Pneumonia | |
|---|---|---|
| Core problem | Sterile chemical injury, often gastric contents | Bacterial infection from colonized oropharyngeal material |
| Pattern | Abrupt decline after a witnessed aspiration; fever or leukocytosis can occur without infection | Infectious syndrome + infiltrate + aspiration risk; event may be unwitnessed |
| First step | Support oxygenation and airway; no prophylactic antibiotics when bacterial infection is not suspected | Community- or hospital-acquired regimen by setting and severity |
| Reassess | Worsening: secondary infection, complication or another diagnosis | Anaerobic coverage only for abscess or empyema; address recurrent aspiration |
-itis is Irritation (support it); -ia is Infection (antibiotics).
-itis chemical injury: support, no prophylactic antibiotics unless infection is suspected-ia bacterial infection: the community- or hospital-acquired regimenAnaerobes only for abscess or empyema
| Risk factor | Related pathogens |
|---|---|
| Alcoholism | Anaerobic oral flora, Klebsiella pneumoniae, Mycobacterium tuberculosis, S. pneumoniae |
| Aspiration | Anaerobic oral flora |
| Bioterrorism | Bacillus anthracis (anthrax), Francisella tularensis (tularemia), Yersinia pestis (plague) |
| Chronic obstructive pulmonary disease or smoking | Chlamydophila pneumoniae, Haemophilus influenzae, Legionella, Moraxella catarrhalis, Pseudomonas aeruginosa or other gram-negative rods, S. pneumoniae |
| Bat or bird droppings | Histoplasma capsulatum |
| Farm animals or parturient cats | Coxiella burnetii (Q fever) |
| HIV, early | H. influenzae, M. tuberculosis, S. pneumoniae |
| HIV, late | Aspergillus, Cryptococcus, H. capsulatum, H. influenzae, Nocardia, nontuberculous mycobacteria, Pneumocystis jirovecii |
| Hotel or cruise ship travel in the past two weeks | Legionella |
| Influenza active in the community | H. influenzae, influenza and other respiratory viruses, S. pneumoniae, Staphylococcus aureus (including methicillin-resistant strains) |
| Injection drug use | Anaerobes, M. tuberculosis, S. aureus (including methicillin-resistant strains), S. pneumoniae |
| Lung abscess | Anaerobic oral flora, M. tuberculosis, nontuberculous mycobacteria, S. aureus (including methicillin-resistant strains) |
| Middle East | Middle East respiratory syndrome |
| Southeast and East Asia | Avian influenza, severe acute respiratory syndrome |
| Southeastern and south-central states bordering the Mississippi and Ohio River basins | Blastomyces dermatitidis |
| Southwestern United States | Coccidioides, Hantavirus |
| Slide 75 places Histoplasma in the Ohio and Mississippi River valleys; this table ties those basins to Blastomyces. Exposure to droppings is the histoplasmosis clue. | |
Link each exposure to one picture: Booze, Barf, Bombs, Butts, Bats and Birds, Barns, the Body’s defenses early and late, Boats, Bugs going round, Needles, Cavities and the map.
Booze alcoholism: anaerobes, Klebsiella, tuberculosis, pneumococcusBarf aspiration: anaerobic oral floraBombs bioterrorism: anthrax, tularemia, plagueButts smoking or chronic obstructive pulmonary disease: Chlamydophila, Haemophilus, Legionella, Moraxella, Pseudomonas, pneumococcusBats and Birds HistoplasmaBarns farm animals or parturient cats: Coxiella (Q fever)Early HIV Haemophilus, tuberculosis, pneumococcusLate HIV Aspergillus, Cryptococcus, Histoplasma, Haemophilus, Nocardia, nontuberculous mycobacteria, PneumocystisBoats hotel or cruise travel: LegionellaBugs going round influenza season: Haemophilus, viruses, pneumococcus, S. aureus incl. methicillin-resistant strainsNeedles injection drug use: anaerobes, tuberculosis, S. aureus incl. methicillin-resistant strains, pneumococcusCavities lung abscess: anaerobes, tuberculosis, nontuberculous mycobacteria, S. aureusMap: Middle East Middle East respiratory syndromeMap: East Asia avian influenza, severe acute respiratory syndromeMap: Mississippi/Ohio basins BlastomycesMap: Southwest Coccidioides, Hantavirus
Where it breaks: A memory scaffold, not a rule: several pathogens repeat across rows, and pneumococcus sits in most of them.
| Decision | Threshold (HIV-associated disease) |
|---|---|
| Treatment | Trimethoprim-sulfamethoxazole preferred, 21 days; intravenous for moderate to severe, then oral; check G6PD (glucose-6-phosphate dehydrogenase) before primaquine or dapsone |
| Add corticosteroids | Room-air PaO2 (arterial oxygen) below 70 mm Hg, or alveolar-arterial gradient 35 mm Hg or more; start early, ideally within 72 hours |
| Start primary prophylaxis | CD4 below 100 cells/mm³, or CD4 100–200 with detectable HIV RNA |
| Antiretroviral therapy | Start within about 2 weeks of diagnosis when feasible |
| The lecturer: the alveolar-arterial gradient “is not going to show up on a test.” | |
70 for steroids, 100 for prophylaxis (200 if the virus is still detectable), 2 weeks to antiretrovirals.
70 room-air arterial oxygen below 70: add steroids100 CD4 below 100: prophylaxis100–200 + virus prophylaxis if HIV RNA detectable2 weeks start antiretroviral therapy
| Letter | High-risk group |
|---|---|
| P | Pregnancy in any trimester and the first 2 weeks postpartum |
| L | Long-term care facility residents |
| I | Immunocompromise from disease or treatment |
| C | Chronic pulmonary, cardiac, renal, hepatic, hematologic, metabolic or neurologic disease |
| O | Severe obesity (and other CDC-listed conditions) |
| 5 | Children younger than 5, especially younger than 2 |
| 65 | Adults 65 or older |
| Recent travel or animal exposure changes testing and public health needs but is not itself a universal severe-disease risk category (slide 98). | |
PLICO, 5 and 65.
P pregnancy and 2 weeks postpartumL long-term careI immunocompromiseC chronic organ diseaseO severe obesity5 under 565 65 or older
| Agent | Use | Avoid / adjust |
|---|---|---|
| Oseltamivir | Preferred: hospitalized, severe or progressive, high-risk, pregnancy; start even after 48 hours; usual course 5 days | Adjust for renal function |
| Baloxavir | Single dose for uncomplicated influenza within 48 hours, age 5 or older | Not in pregnancy, breastfeeding, severe immunosuppression or hospitalized; no polyvalent cations together |
| Inhaled zanamivir | Other option | Avoid in asthma or COPD (chronic obstructive pulmonary disease): bronchospasm |
| Intravenous peramivir | Eligible outpatients, uncomplicated influenza | Adjust for renal function |
| Amantadine, rimantadine | — | Not recommended (resistance) |
| Supportive care: avoid aspirin under 18 (Reye syndrome); antibiotics only for proven or suspected bacterial pneumonia (slide 110). | ||
O is for Ordinary and the very sick; B is one-and-done but Bars the Bump, Breastfeeding, the Bedbound and the Badly immunosuppressed; Z wheezes; P needs kidneys checked; A and R are Retired.
O oseltamivir: preferred, pregnancy, hospitalizedB baloxavir: single dose; not pregnancy, breastfeeding, hospitalized, severe immunosuppressionZ zanamivir: avoid in asthma or COPDP peramivir: renal adjustmentA and R amantadine, rimantadine: resistance
| Class | Criteria |
|---|---|
| Asymptomatic or presymptomatic | Infection without symptoms |
| Mild | Some symptoms, no dyspnea, normal chest film |
| Moderate | Some symptoms, positive film, oxygen saturation at least 94% on room air |
| Severe | Saturation below 94% on room air, marked tachypnea, infiltrates over 50% of lung volume |
| Critical | Acute respiratory failure, septic shock or multiple organ dysfunction |
Film splits mild from moderate; 94 and 50 split moderate from severe; failure makes it critical.
None asymptomaticNormal film mildAbnormal film, 94%+ moderateBelow 94%, marked tachypnea, over 50% infiltrates severeFailure, shock, organs critical
| Early outpatient pathway | Hospital pathway | |
|---|---|---|
| Who | High-risk patient, mild or moderate disease, no hypoxemia | Hypoxemia, severe respiratory disease or critical illness |
| Treatment | Nirmatrelvir/ritonavir within 5 days or 3-day remdesivir within 7 days of onset; molnupiravir (adults) only if these are unsuitable | Dexamethasone; consider remdesivir by timing and support; baricitinib or tocilizumab plus steroids for rapid progression |
| Checks | Drug interactions, renal dosing, hepatic contraindications before nirmatrelvir/ritonavir; molnupiravir: avoid in pregnancy | Venous thromboembolism prophylaxis unless contraindicated; therapeutic dosing needs a thrombosis and bleeding assessment, not D-dimer alone |
| Avoid | No systemic steroids without hypoxemia unless another indication | — |
N in 5, R in 7, M only as Last resort (never the Mother-to-be); Dexamethasone needs Desaturation.
N in 5 nirmatrelvir/ritonavir within 5 daysR in 7 remdesivir (3 days) within 7 daysM molnupiravir: last resort, avoid in pregnancyD dexamethasone only with hypoxemia
| Stage | Description |
|---|---|
| 1 | Flulike syndrome without radiographic abnormalities |
| 2 | Mild-to-moderate pneumonia |
| 3 | Severe pneumonia |
| 4 | Acute respiratory failure, sepsis and septic shock |
Flu, Fair, Fierce, Failure.
Flu flulike, normal filmFair mild to moderate pneumoniaFierce severe pneumoniaFailure respiratory failure, sepsis, septic shock
| Disease and severity | Treatment |
|---|---|
| Histoplasmosis, mild acute, immunocompetent adult | Often observation, not antifungals |
| Histoplasmosis, prolonged or progressive, or higher-risk host | Consider itraconazole (monitor interactions and levels) |
| Histoplasmosis, severe pulmonary or disseminated | Specialist-led amphotericin-based induction |
| Histoplasmosis, chronic cavitary | Prolonged azole, usually at least 12 months |
| Cryptococcosis, mild isolated pulmonary | Fluconazole, generally 6–12 months |
| Cryptococcosis, severe pulmonary, central nervous system or disseminated | Liposomal amphotericin B plus flucytosine induction, then fluconazole; infectious disease consultation |
| Slide 78: the 2025/2026 updates replace a simple “4-week symptom” treatment rule for histoplasmosis. | |
Mild histo: Mind it (watch). Lingering: Itra. Life-threatening: Ampho. Crypto mild: Flu-con; crypto bad: Ampho + Flucytosine, then Flu-con.
Watch mild histoplasmosisItra prolonged or higher-risk histoplasmosisAmpho severe or disseminated histoplasmosis12 months chronic cavitary histoplasmosisFlu-con mild pulmonary cryptococcosisAmpho + flucytosine severe or central nervous system cryptococcosis
| Decision | Useful test | What changes |
|---|---|---|
| Is pneumonia present? | Chest radiograph; lung ultrasound with expertise | Confirms a parenchymal process vs bronchitis or another diagnosis |
| Where to treat? | Saturation, vital signs, organ dysfunction, sepsis assessment, Pneumonia Severity Index plus judgment | Outpatient vs ward vs intensive care |
| Will it change therapy or precautions? | Molecular viral testing; cultures for severe community-acquired pneumonia or validated resistance risk | Antivirals, infection prevention, targeted coverage, de-escalation |
| Atypical or complicated course? | Computed tomography for uncertainty, cavitation, obstruction, abscess or empyema; targeted tests by exposure or immune status | Drainage, duration, consultation, organism-specific treatment |
PAWS before you order: Present? Admit where? Would it change therapy? Strange course?
P is pneumonia present: filmA admit where: saturation, vitals, severity indexW would it change therapy: viral test, selective culturesS strange course: computed tomography, targeted tests
| Withhold or stop | Do not withhold |
|---|---|
| Uncomplicated acute bronchitis (whatever the sputum color or duration) | Suspected bacterial pneumonia: community- or hospital-acquired pathway promptly |
| Chemical aspiration pneumonitis: supportive care | Severe or unstable patient: specimens without delaying empiric therapy |
| Influenza or COVID-19 without bacterial complication: antiviral pathway | Aspiration pneumonia, abscess or empyema (anaerobes for abscess or empyema) |
| Selected viral-positive outpatient community-acquired pneumonia, no comorbidities, close follow-up | A worsening course: reassess, do not just add drugs |
| Antibiotics treat a bacterial syndrome, not cough duration, sputum color, a positive viral test or inflammation alone. Safety net: expected course, return precautions, a reassessment plan. | |
Hold for the 4 C’s that are not bacteria: Chest cold, Chemical burn, Corona or flu, a Clean viral outpatient. Give for the 4 S’s: Suspected bacteria, Sick or unstable, Suppuration (abscess, empyema, aspiration pneumonia), Sliding downhill.
Chest cold acute bronchitisChemical burn aspiration pneumonitisCorona or flu viral, no bacterial complicationClean viral outpatient viral-positive community-acquired pneumonia, no comorbidities, follow-upSuspected bacteria bacterial pneumoniaSick severe or unstableSuppuration aspiration pneumonia, abscess, empyemaSliding worsening course
| Stage | What the slides say |
|---|---|
| Primary infection | Initial infection may remain contained without clinical disease |
| Progressive primary tuberculosis | Disease develops soon after initial infection when immune containment fails |
| Latent tuberculosis infection | Infected but asymptomatic; not infectious, cannot spread it; no evidence of disease after evaluation |
| Reactivation (secondary) tuberculosis | Latent infection progresses to disease, often with impaired immunity; reinfection is a separate event |
Caught, Crashed early, Caged, Came back.
Caught primary infection, containedCrashed early progressive primary tuberculosisCaged latent infection: no symptoms, no spreadCame back reactivation (secondary), with impaired immunity
| Latent tuberculosis infection | Tuberculosis disease | Nontuberculous mycobacterial disease | |
|---|---|---|---|
| Symptoms | None | Persistent cough, fever, night sweats, weight loss (may be mild or absent) | Chronic cough and sputum, fatigue, weight loss, dyspnea or hemoptysis |
| Spreads? | No | Yes if pulmonary or laryngeal (airborne) | Person-to-person spread uncommon (environmental) |
| Skin or blood test | Positive (shows infection only) | Can be falsely negative (immunosuppression, severe tuberculosis); a negative never rules disease out | — |
| Chest imaging | Usually normal | Infiltrates, cavities (upper lobes after primary), adenopathy, effusion, miliary nodules | Nodular bronchiectasis or fibrocavitary disease on computed tomography |
| Microbiology | No evidence of disease | 3 sputum specimens: smear, culture, rapid molecular test, susceptibility | Same species in 2 or more sputum cultures, or 1 wash or lavage or biopsy |
| Treatment | 3HP, 4R or 3HR (6H or 9H if rifamycins unsuitable) after excluding disease | 2 months HRZE, then 4 months HR; isolation and notification | Macrolide-susceptible Mycobacterium avium complex: azithromycin, ethambutol, rifamycin, at least 12 months after culture conversion |
| An acid-fast smear cannot tell tuberculosis from nontuberculous mycobacteria (slide 4). Regimen letters are expanded in the regimen tables below. | |||
Latent is Locked (no symptoms, no spread, normal film); Disease Disperses (symptoms, sputum, isolation); Nontuberculous comes from Nature (environment, needs repeat cultures).
Locked latent infectionDisperses tuberculosis diseaseNature nontuberculous mycobacterial disease
| Tier | Letter | Risk factor |
|---|---|---|
| Higher | H | HIV (human immunodeficiency virus) infection or major immunosuppression |
| Higher | I | Immunosuppressive treatment: TNF (tumor necrosis factor) inhibitors, transplantation, prolonged corticosteroids |
| Higher | R | Recent infection, especially within 2 years |
| Higher | E | Early life: infancy and young childhood |
| Additional | D | Diabetes mellitus |
| Additional | K | Chronic kidney disease or dialysis |
| Additional | M | Silicosis, low body weight or malnutrition (the lungs and the meal) |
| Additional | S | Smoking (tobacco) and harmful alcohol use |
Higher risk HIREs it; Don’t Keep Missing Smokers.
H HIV or major immunosuppressionI TNF inhibitors, transplant, prolonged steroidsR recent infection within 2 yearsE infancy and young childhoodD diabetesK kidney disease or dialysisM silicosis, low weight, malnutritionS tobacco and harmful alcohol
Where it breaks: M packs three slide items (silicosis, low body weight, malnutrition) and S packs two (tobacco, alcohol).
| Step | Rule (slide 20) |
|---|---|
| Place | 0.1 mL purified protein derivative intradermally on the forearm |
| Read | A trained reader at 48–72 hours |
| Measure | Transverse induration in millimeters; do not measure erythema |
| Interpret | By the patient’s risk category (the 5, 10, 15 mm table) |
| BCG (bacille Calmette-Guérin) history | Can cause a false-positive skin test; use the same thresholds regardless; interferon-gamma release assay preferred for most vaccinated patients (slide 21) |
Point-one in, two to three days, feel the bump not the blush.
Point-one 0.1 mL intradermal, forearmTwo to three days read at 48–72 hoursBump not blush measure induration, not erythemaRisk group interpret by categoryBCG same thresholds; prefer the blood test
| Induration | Positive in |
|---|---|
| 5 mm or more | HIV, recent close contact, transplant, major immunosuppression, or imaging suggesting prior tuberculosis |
| 10 mm or more | Increased exposure risk, selected medical risks, high-risk congregate settings, children under 5 or children exposed to high-risk adults |
| 15 mm or more | No known tuberculosis risk factors |
5 for the Sick and the Close, 10 for the Risky, 15 for the Rest.
5 immune-weak (HIV, transplant, immunosuppressed), close contacts, imaging suggesting prior tuberculosis10 exposure risk, medical risk, congregate settings, children under 515 no risk factors
Where it breaks: “Selected medical risks” is all the slide says for the 10 mm group; major immunosuppression is a 5 mm group.
| Situation | What to do |
|---|---|
| Recent exposure (early infection) | Repeat 8–10 weeks after the last exposure when indicated |
| Immunosuppression or severe tuberculosis | False negatives possible |
| Symptoms or high clinical suspicion | Evaluate for disease now; symptoms or suspicious imaging need microbiologic testing even with a negative skin or blood test |
| Young child or immunocompromised contact | Prompt public-health assessment |
| Blood test indeterminate, invalid or borderline | Repeat it, or use a skin test |
| Blood test negative | Infection less likely, but disease still possible |
Too Early, Too Weak, Too Sick, Too Young: a negative is not the end.
Too early repeat 8–10 weeks after exposureToo weak immunosuppression or severe tuberculosis: false negativeToo sick symptoms or high clinical suspicion: evaluate for disease nowToo young young or immunocompromised contacts: public health nowUnclear blood test repeat or use the skin testNegative blood test disease still possible
| Tuberculin skin test | Interferon-gamma release assay | |
|---|---|---|
| Detects | Immune response to infection | Immune response to tuberculosis-specific antigens (blood) |
| Latent vs disease? | Cannot tell | Cannot tell |
| BCG vaccine | Can cause a false positive | Does not cause a positive: preferred after BCG |
| Visits | Placement, then a reading at 48–72 hours | One visit |
| After treatment | May stay positive | May stay positive: monitor by clinical and microbiologic response |
Both only say “infected”; the Blood test Beats BCG in one visit.
Infected only neither separates latent from diseaseBlood beats BCG no false positive after BCGOne visit blood testStays positive do not use either to monitor treatment
| Step | Rule |
|---|---|
| Collect | 3 sputum specimens, 8–24 hours apart, at least one early morning |
| Smear and culture | Acid-fast bacilli smear and mycobacterial culture |
| Molecular | A rapid molecular test on at least one respiratory specimen |
| Susceptibility | Molecular and culture-based drug-susceptibility testing |
| HIV | Offer HIV testing when status is unknown |
3-8-1, then SMASH: 3 specimens, 8–24 hours apart, 1 in the morning; Smear (and culture), Molecular, Susceptibility, HIV.
3-8-1 3 specimens, 8–24 hours apart, 1 early morningS smear (and culture)M rapid molecular testS susceptibility testingH HIV test
| Picture | Typical findings |
|---|---|
| Primary disease | Hilar or mediastinal adenopathy, infiltrates or effusion |
| Post-primary disease | Upper lobes, may cavitate |
| Miliary disease | Diffuse tiny nodules |
| HIV or other immunosuppression | Atypical patterns |
| Latent infection | Usually a normal film |
| Prior tuberculosis | Scarring, volume loss, calcified granulomas (review prior treatment, exclude active disease) |
| Imaging supports suspicion but cannot confirm tuberculosis or reliably determine activity, and cannot tell recent infection, reactivation or reinfection apart. | |
Primary Puffs the hilum; Post-primary Punches holes up top; Miliary is Millet seeds.
Primary hilar or mediastinal nodes, infiltrates, effusionPost-primary upper-lobe cavitiesMiliary diffuse tiny nodulesImmunosuppressed atypicalLatent normal filmOld scar, volume loss, calcified granulomas
| Letter | Action |
|---|---|
| N | Notify the local or state tuberculosis program of presumed or confirmed tuberculosis |
| A | Airborne infection isolation room when indicated |
| N | Staff wear a fit-tested N95 or higher-level respirator |
| S | Patient source control during transport |
| E | End isolation by clinical, laboratory and public-health criteria, not a fixed treatment interval |
NANSE: Notify, Airborne room, N95, Source control, End by criteria.
N notify the programA airborne isolation roomN N95 respiratorS source control in transportE end by criteria, not by a calendar
| Regimen | Drugs and length |
|---|---|
| Standard (slide 34) | 2 months HRZE: isoniazid (H), rifampin (R), pyrazinamide (Z), ethambutol (E); then 4 months HR; ethambutol stops once isoniazid and rifampin susceptibility is established; daily therapy with directly observed therapy (in person or by video) supports completion |
| 17-week (slide 35) | Age 12 or older, susceptible pulmonary disease: 8 weeks isoniazid, rifapentine, pyrazinamide, moxifloxacin; then 9 weeks isoniazid, rifapentine, moxifloxacin |
| Selected children, nonsevere (slide 35) | 4 months: 2 months isoniazid, rifampin, pyrazinamide (with or without ethambutol), then 2 months isoniazid and rifampin |
| Resistance and monitoring (slide 36) | Rifampin resistance: rapid susceptibility testing and expert management; review at least monthly; sputum cultures until conversion, response documented at 2 months; watch liver injury, interactions, toxicity |
RIPE for 2, then RI for 4; E Exits early once susceptibility is known.
R rifampinI isoniazid (H)P pyrazinamide (Z)E ethambutol, stops after susceptibility2 + 4 6 months total17 weeks 8 + 9, age 12 or older
Where it breaks: The slide writes the regimen as HRZE; RIPE is the same four drugs in a different order.
| Code | Regimen | Use |
|---|---|---|
| 3HP | Weekly isoniazid plus rifapentine for 3 months | Preferred short regimen |
| 4R | Daily rifampin for 4 months | Preferred short regimen |
| 3HR | Daily isoniazid plus rifampin for 3 months | Preferred short regimen |
| 6H or 9H | Isoniazid for 6 or 9 months | When rifamycin regimens are unsuitable |
| First exclude tuberculosis disease; check interactions, pregnancy considerations and source-case resistance. | ||
The number is the months; H = isoniazid, R = rifampin, P = rifapentine; drop the rifamycin and the months go up (6H, 9H).
3HP 3 months, weekly isoniazid + rifapentine4R 4 months, daily rifampin3HR 3 months, daily isoniazid + rifampin6H / 9H isoniazid alone, rifamycin unsuitable
| Domain | Requirement |
|---|---|
| Symptoms and imaging | Compatible symptoms and imaging (nodular bronchiectasis or fibrocavitary disease) |
| Something else excluded | Alternative diagnoses excluded |
| Same species | Usually 2 or more sputum cultures with the same species, or one positive bronchial wash or lavage or qualifying biopsy |
| MAC (Mycobacterium avium complex) treatment | Macrolide-susceptible: azithromycin, ethambutol and a rifamycin, at least 12 months after culture conversion; cavitary or severe: may need daily therapy and initial intravenous amikacin; still positive after 6 months or more: may warrant inhaled liposomal amikacin |
| A respiratory isolate alone does not prove disease (slide 38): all domains are required. | |
Three S’s to diagnose (Symptoms and Scan, Something else excluded, Same species twice); A-E-R for 12 after conversion.
S symptoms and scanS something else excludedS same species twice, or one wash, lavage or biopsyA-E-R azithromycin, ethambutol, rifamycin12 months after culture conversion
| Term | What you need to know |
|---|---|
| ★ Indications | Hypoxia; acute medical or surgical needs (perioperative, postoperative); respiratory conditions (carbon monoxide poisoning); special indications without hypoxia: air hunger (end of life) and cluster headache. “One of the big things.” |
| ★ Fire | Benefit: correction of hypoxia, symptom relief, therapeutic benefit. Risk: fire hazard — “probably one of the biggest risks.” Also hypercapnia (carbon dioxide retention), mucosal irritation, vasoconstriction. |
| Myocardial infarction | Vasoconstriction: not given unless saturation is below 91% (the slide’s value; current guidelines use 90%). |
| ★ Home qualification | Documented hypoxia by arterial blood gas or pulse oximetry at rest, with exertion and/or during sleep, performed at the time of need. Rest: saturation ≤ 88% on room air or partial pressure of oxygen ≤ 55 mm Hg. Exertion: ≤ 88% and improves with oxygen. Sleep: ≤ 88% with a drop of 5% or more. |
| Group I vs II | Group I (qualifies): ≤ 55 mm Hg or ≤ 88% → recertify at 12 months. Group II (conditional): 56–59 mm Hg or 89% plus pulmonary hypertension, cor pulmonale (right heart failure) or polycythemia (hematocrit above 56%) → recertify at 3 months. |
| Term | What you need to know |
|---|---|
| Varies or fixed | Nasal cannula, simple mask: fraction varies with respiratory rate, inspiratory flow, tidal volume. Partial rebreather, non-rebreather: varies with patient demand. Air entrainment (Venturi, air-entrainment nebulizer): fixed, does not fluctuate. |
| Nasal cannula | Low flow, 1–6 L/min, 24–44% (room air 21%; about +4% per liter: 1 = 24, 2 = 28, 3 = 32, 4 = 36, 5 = 40, 6 = 44). Maxes at 44% even above 6 L/min. Humidity above 4 L/min. Mild hypoxia; most commonly used. |
| Simple mask | Low flow, 5–10 L/min, .35–.50 (5–6 L/min 35%, 6–7 40%, 7–8 50%). Mild to moderate respiratory distress. |
| Partial rebreather | Some exhaled gas gets into the reservoir bag; not commonly used. Its fraction differs between slides (60–80% vs .40–.70): never tested. |
| Non-rebreather | Low flow device, but with a high fraction: 10–15 L/min = 60–100%. Reservoir bag + one-way valve (no inhaling exhaled air). Flow set to keep the bag from collapsing. Severely hypoxic patients still ventilating well. |
| Venturi mask | High flow, precise; ports change the fraction; 4–10 L/min → 24–50%; total flow above inspiratory demand. Chronic obstructive pulmonary disease (precision). |
| Air-entrainment nebulizer | Aerosol mask, open face mask, T-piece, tracheostomy collar. Can deliver higher but not recommended above .50. |
| Advanced airways | Bag-valve mask (resuscitator bag); oropharyngeal and nasopharyngeal airways; endotracheal tube, tracheostomy; tube changer and bougie; laryngeal mask airway. |
| Term | What you need to know |
|---|---|
| Why a nebulizer | Liquid medication directly to the airways; medication chosen for the specific treatment; secretion clearance; inhalers are challenging in certain situations; severe exacerbations of respiratory illness. |
| Is it working? | Clinical: symptoms, work of breathing, color and perfusion. Objective: saturation improves (target varies); blood gas shows a higher oxygen without a higher carbon dioxide and a corrected pH. Vital signs; watch for complications. |
| ★ Home safety | Highly flammable, compressed gas. No smoking; “No Smoking” and “Oxygen in Use” signs. At least 10 feet from heat sources (pilot lights, electric appliances, candles). No petroleum products (lip balms, lotions, oils, grease). Smoke and carbon monoxide alarms tested monthly. Proper storage and disposal. |
| Term | What you need to know |
|---|---|
| ★ Normal values | pH 7.35–7.45 (“burn this into your eyeballs”); carbon dioxide 36–44 mm Hg (midpoint 40); bicarbonate 22–26 mEq/L (midpoint 24). Acidemia below 7.35, alkalemia above 7.45. |
| ★ Winter formula | Metabolic acidosis: expected carbon dioxide = 1.5 × bicarbonate + 8, ± 2. Higher than expected = added respiratory acidosis, can signal impending respiratory failure. |
| ★ Anion gap | Sodium − (chloride + bicarbonate), normal 9–15. Above 15 = elevated-gap acidosis. |
| ★ Treatment | “Always going to be correct the underlying disorder.” Therapy aimed at the pH itself only when it is unsustainable: below 6.7 or above 7.6. |
| ★ Frequent questions | Obesity hypoventilation triad; paper bag = placebo; saline responsive is the common alkalosis; carbon dioxide rarely above 55 in compensation; urine chloride splits the alkaloses. |
| Term | What you need to know |
|---|---|
| Steps | 1. pH: acidosis or alkalosis. 2. Which value (carbon dioxide or bicarbonate) matches the pH. 3. Mixed? pH more or less than expected. 4. Compensation: respiratory disorder → expected bicarbonate; metabolic disorder → expected carbon dioxide. 5. Don’t neglect the patient. |
| Rules | Compensation never returns pH to normal and never past it; respiratory cause → renal compensation; metabolic cause → respiratory compensation. Normal pH with abnormal values = mixed disorder. |
| Ratios (given in questions) | Respiratory acidosis: bicarbonate +1 per 10 mm Hg acute, +3.5 chronic. Respiratory alkalosis: −2 per 10 acute, −5 chronic. Metabolic acidosis: carbon dioxide −1.3 per 1 mEq/L (use Winter). Metabolic alkalosis: +0.75 per 1 mEq/L, rarely above 55 (above = concurrent respiratory acidosis). |
| Timing | Renal compensation begins 6–12 hours after onset, complete over days: small bicarbonate change = acute, large = chronic. |
| Algorithm | pH below 7.4 + carbon dioxide above 40 = respiratory acidosis (acute or chronic?); below 40 = compensating metabolic acidosis (check the gap). pH above 7.4 + carbon dioxide above 40 = compensating metabolic alkalosis; below 40 = respiratory alkalosis. |
| Term | What you need to know |
|---|---|
| Respiratory acidosis | Hypoventilation → carbon dioxide above 40 → low pH, ± hypoxemia. Somnolence, confusion, altered mental status, asterixis, myoclonus; severe: raised cerebral blood flow and intracranial pressure, papilledema. Labs: low pH, high carbon dioxide, high bicarbonate, hypochloremia if chronic (ammonium chloride excretion). |
| Acute causes | Airway obstruction; pneumonia, asthma, pulmonary edema, aspiration pneumonitis; central nervous system depression (recreational drugs, intracranial catastrophe, intravenous sedation); myasthenia gravis, Guillain-Barré syndrome; pneumothorax, flail chest. |
| Chronic causes | Chronic obstructive pulmonary disease (“first thing that comes to mind”), interstitial lung disease, idiopathic pulmonary fibrosis; muscular dystrophy, amyotrophic lateral sclerosis; ★ obesity hypoventilation (Pickwickian) syndrome: obesity + sleep disordered breathing + chronic hypercapnia. |
| Treat | Underlying cause. Acute: restore ventilation. Chronic: careful oxygen titration; avoid rapid carbon dioxide reduction → post-hypercapnic metabolic alkalosis. |
| Respiratory alkalosis | Hyperventilation → low carbon dioxide → high pH. Light-headedness, anxiety, perioral numbness, paresthesias; severe: tetany (high pH binds calcium to albumin). Compensation: cells trade hydrogen ions for potassium, then kidneys excrete bicarbonate and keep chloride (low bicarbonate, hypokalemia, hyperchloremia). |
| Alkalosis causes | Psychogenic, stroke, raised intracranial pressure; hypoxia (high altitude, severe anemia, ventilation-perfusion mismatch, hypotension); salicylates, caffeine, nicotine, catecholamines, thyroxine; pulmonary embolism, pneumonia, pulmonary edema, mechanical hyperventilation, interstitial lung disease; pregnancy, hyperthyroidism; septicemia, heat exposure, hepatic failure. |
| Treat | Underlying cause; usually self-limited. ★ Paper bag not necessary: does not correct carbon dioxide, may lower oxygen, placebo. Rapid correction of chronic alkalosis → post-hypocapnia metabolic acidosis. |
| Term | What you need to know |
|---|---|
| Metabolic alkalosis | High bicarbonate → high pH. No characteristic findings; orthostatic hypotension; hypokalemia → weakness, hyporeflexia. Labs: high pH and bicarbonate, raised carbon dioxide, low potassium, low chloride. |
| ★ Urine chloride | Below 25 mEq/L = saline responsive (more common; volume contraction): diuretics, post-hypercapnia, vomiting or nasogastric suction, antacids, volume contraction. Above 40 = saline unresponsive (euvolemic or hypervolemic) → check blood pressure. |
| Unresponsive groups | Normotensive: severe potassium depletion; hypoparathyroidism and hypercalcemia. Hypertensive: primary aldosteronism, exogenous alkali, mineralocorticoids, licorice (“a unicorn”). |
| Treat alkalosis | Underlying cause; saline responsive: isotonic saline and stop diuretics. |
| Metabolic acidosis | Low bicarbonate → low pH, low carbon dioxide; hyperkalemia may be present. Signs of the cause + compensatory hyperventilation; Kussmaul respirations (increased tidal volume and tachypnea) in diabetic ketoacidosis. Normal gap = hyperchloremic; elevated gap = normochloremic. |
| Elevated gap: MUDPILES | Methanol, metformin · uremia · diabetic ketoacidosis · paraldehyde · isoniazid, iron · lactic acidosis · ethylene glycol · salicylates, starvation. |
| Normal gap: USEDCAR | Ureteral diversion · saline infusion · exogenous acid · diarrhea · carbonic anhydrase inhibitors · adrenal insufficiency · renal tubular acidosis (bicarbonate loss, chloride retention). |
| Gap pitfalls | Albumin makes most of the normal gap; hypoalbuminemia, sodium extremes and antibiotics distort it. A normal gap does not exclude acidosis and should not override clinical concern. Fewer unmeasured cations (calcium, magnesium, potassium) raise it. |
| Term | What you need to know |
|---|---|
| Potassium | Acidosis: hydrogen into cells, potassium out → hyperkalemia. Alkalosis: potassium into cells → hypokalemia. |
| Oxygen | Acidosis: lower hemoglobin affinity, curve right, more oxygen to tissues. Alkalosis: higher affinity, curve left, less oxygen to tissues. |
| Unsustainable pH | Below 6.7 or above 7.6: cardiac hypocontractility and irritability, seizures, cerebral edema, metabolic disturbances. |
| Buffers | Chemical buffering (extracellular, intracellular), respiratory (carbon dioxide, fast), renal (bicarbonate, hours to days). Water + carbon dioxide ↔ carbonic acid ↔ hydrogen ion + bicarbonate. Brainstem chemoreceptor: more carbon dioxide → lower cerebral pH → more breathing. Hypercapnia usually from under-excretion. |
| Term | What you need to know |
|---|---|
| ★ Severity from a description | Table for 12 years and older; severity goes to the most severe category in which any feature occurs. Intermittent = “rule of twos” (2 or fewer days/week, 2 or fewer nights/month). Focus on mild and moderate. |
| ★ Persistent cut-offs | Mild: symptoms more than 2 days/week but not daily; 3–4 nights/month; 1-second volume above 80%. Moderate: daily; more than once/week but not nightly; 60–80%. Severe: all day; often 7/week; below 60%. |
| ★ Patient education | Written action plan; inhaler, spacer and nebulizer technique; peak flow zones; triggers; rinse the mouth after an inhaled steroid; vaccines. “Really important is the patient education.” |
| ★ Classes, not brands | Know the class: short-acting beta-2 agonist (rescue), inhaled corticosteroid (first-line controller), long-acting beta-2 agonist (never alone), leukotriene modifier (add-on). |
| Not tested | Epidemiology numbers; emergency management (slides 97–105); age-normal ratio values; any question with conflicting rescue-inhaler guidance. |
| Term | What you need to know |
|---|---|
| Definition | Chronic inflammatory airway disorder, reversible obstruction (some long-standing cases irreversible); trouble getting air out. Hyper-responsiveness: excessive constriction to a trigger a normal airway ignores. |
| Course | Any age, peak 3 years; may quiet in adolescence and return. Severity rarely changes: mild rarely becomes severe; severe usually severe at onset. |
| Death risk | Frequent bronchodilator use; no or poorly taken inhaled steroid; previous near-fatal admission. |
| Extrinsic vs intrinsic | Extrinsic: allergen-triggered, atopic, most common (atopic triad: rhinitis, asthma, eczema). Intrinsic: about 10%, adult onset, negative skin tests, normal immunoglobulin E, nasal polyps, may be aspirin sensitive. |
| Other types | Occupational (better weekends and vacations); catamenial (menstrual cycle); “cardiac” (decompensated heart failure); exercise-induced (starts within 3 minutes, peaks 10–15, gone by 60); aspirin-sensitive (1–5%, minutes to 12 hours). |
| Triggers | Dust mites (most common), pet dander, cockroaches, pollens, fungal spores; viruses; aspirin and beta blockers; exercise; cold air; pollution; smoke; stress; occupational agents. |
| Risk factors | Atopy; obesity (body mass index above 30); early viral infection. Allergen avoidance does not prevent asthma; early exposure may protect. |
| Term | What you need to know |
|---|---|
| Exam | Often normal between attacks. Exacerbation: accessory muscles, leaning forward; wheeze may vanish (decreased breath sounds, prolonged expiration). Worse at night (peak 3–4 am). |
| Spirometry | Before and after a short-acting bronchodilator; reduced 1-second volume and ratio; 12% or more improvement supports asthma. Effort-dependent: coach. Repeat yearly. |
| Other tests | Provocation (methacholine, histamine) if spirometry is not diagnostic, not below 65% predicted; exercise challenge for exercise-induced bronchospasm; allergy testing for triggers; exhaled nitric oxide = inflammation; chest x-ray normal or hyperinflated. |
| Peak flow | Home baseline; morning before, afternoon after the bronchodilator; 20% change between them or day to day = poor control. |
| Action plan | Green 80% or more of personal best; yellow 50–79% (add quick-relief, keep controller); red under 50%, very short of breath or quick-relief failing (medical alert). Danger signs: cannot walk or talk, blue lips or nails. |
| Visit sequence | Initial: diagnose, classify, start medicine and demonstrate, written plan, schedule follow-up. Follow-up: control, compliance, adjust, update plan. |
| Differential | Vocal fold dysfunction or paralysis, foreign body, laryngotracheal mass; chronic obstructive pulmonary disease, bronchiectasis, cystic fibrosis; conversion disorder, emotional laryngeal wheezing, factitious disorder; aspergillosis. |
| Aspergillosis | Allergic bronchopulmonary aspergillosis: hypersensitivity to Aspergillus fumigatus, almost only in asthma or cystic fibrosis; vigorous immunoglobulin E and G response; exacerbations. |
| Term | What you need to know |
|---|---|
| Rescue | Every patient needs a short-acting beta-2 agonist (albuterol); 3–6 hours; before exercise prevents exercise-induced bronchospasm; rising use = poor control; tremor, palpitations. |
| Inhaled corticosteroid | Preferred first-line for persistent asthma; twice daily; full effect takes months; hoarseness, cough, thrush → spacer, rinse and spit. |
| Systemic steroid | Exacerbations: short course, no taper. Long-term only if refractory, minimum dose, with calcium and vitamin D. Side effects: truncal obesity, osteoporosis, bruising, ulcers, depression, hypertension. |
| Long-acting beta-2 agonist | Up to 12 hours; never alone (no anti-inflammatory effect); pair with inhaled steroid. |
| Other controllers | Cromolyn: prevents, does not relieve. Tiotropium: slow, weak, few side effects. Theophylline: narrow range; nausea, vomiting, arrhythmias, seizures, high glucose, low potassium. Leukotriene modifiers: add-on, helpful for exercise-induced. Monoclonal antibodies: specialist, spare steroids. |
| Avoid | Aspirin and non-selective anti-inflammatory drugs (ibuprofen, naproxen, diclofenac, indomethacin) in aspirin-sensitive asthma; selective ones (celecoxib, meloxicam) allowed. Beta blockers. |
| Immunotherapy & vaccines | Immunotherapy: allergic triggers, single allergen, controlled setting only. Influenza yearly and pneumococcal; caution with intranasal influenza vaccine. |
| Poor control | Check compliance and technique first (most common reason); steroid resistance is very rare; refractory asthma → specialist. |
| Term | What you need to know |
|---|---|
| ★ Diagnosis | Spirometry before and after a bronchodilator: ratio of 1-second volume to forced vital capacity below 0.70; response under 12% = irreversible. Chronic bronchitis without obstruction is not this disease. |
| ★ Airflow grade | Post-bronchodilator 1-second volume: 1 mild ≥80%; 2 moderate 50–79%; 3 severe 30–49%; 4 very severe <30%. |
| ★ Symptoms & risk | Assessment test ≥10 or dyspnea grade ≥2 = more symptoms. High risk = 2 or more moderate exacerbations or 1 hospitalization. |
| ★ Groups | 2020: A low/low, B high symptoms/low risk, C low symptoms/high risk, D high/high. 2023–2026: A, B, and E = any high risk. “S × R = group.” |
| ★ Start | A: one bronchodilator. B: long-acting beta agonist + long-acting antimuscarinic. E: that pair, add inhaled steroid if eosinophils ≥300. |
| ★ Survival | Only smoking cessation, long-term oxygen (severe resting hypoxemia) and noninvasive ventilation (hypercapnic exacerbation) improve survival. |
| Term | What you need to know |
|---|---|
| Definition | Persistent airflow obstruction + respiratory symptoms from inhaled particles; umbrella of chronic bronchitis (cough ≥3 months/year for 2 years) and emphysema (alveolar destruction). |
| Blue bloater | Chronic bronchitis: sputum, rhonchi, cyanosis, edema; early hypoxemia and hypercapnia; normal diffusing capacity; bronchial wall thickening. |
| Pink puffer | Emphysema: thin, pursed lips, barrel chest, distant sounds, hyperresonance; gas exchange late; reduced diffusing capacity; flat diaphragm, bullae. |
| Causes | Tobacco ~90% (primary); biomass smoke (low-income countries, never-smokers); coal, gold mining, welding; inactivity. Cessation is the key treatment. |
| Alpha-1 antitrypsin deficiency | Age ≤45, nonsmoker, basilar panlobular emphysema, family history; level <11 micromol/L + deficient genotype. Smokers: centrilobular, upper lobe. |
| Early sign | Dyspnea on exertion. Not always thin; not always productive. Pursed lips keep airways open. Screen: heart disease, lung cancer, osteoporosis, depression, reflux, anemia. |
| Exam extras | Flat diaphragm → lower intercostal retraction on inspiration; neck veins distend in expiration; cor pulmonale; syncope and falls (poor perfusion). |
| Term | What you need to know |
|---|---|
| Patterns | Low ratio = obstruction. Obstruction + low forced vital capacity = possible mixed (confirm with total lung capacity). Normal ratio + low forced vital capacity = possible restriction. |
| Physiology | Air trapping (residual volume up), hyperinflation, dynamic hyperinflation with exertion; scooped expiratory limb. |
| Other tests | Blood gas only if deteriorating (carbon dioxide >45, bicarbonate up = compensatory metabolic alkalosis); blood count (anemia, eosinophils); B-type natriuretic peptide for heart failure; chest film rules out other causes; computed tomography rarely needed. |
| Scores | BODE (body mass index, obstruction, dyspnea, exercise) → 4-year survival: 0–2 = 80%, 3–4 = 67%, 5–6 = 57%, 7–10 = 18%. 1-second volume ≥65 = 0, 50–64 = 1, 36–49 = 2, ≤35 = 3; walk ≥350 m = 0, 150–249 = 2, ≤149 = 3; dyspnea 0–1 = 0, 2 = 1, 3 = 2, 4 = 3; body mass index ≤21 = 1. |
| Term | What you need to know |
|---|---|
| Non-drug | Cessation (essential, all groups, with counseling); rehabilitation essential for B and E; activity; yearly influenza vaccine; pneumococcal at 65 (earlier if 1-second volume <40% or cardiac disease). |
| Five A's / FRAMES | Ask, Advise, Assess, Assist, Arrange. Feedback, Responsibility, Advice, Menu, Empathy, Self-efficacy. |
| Drug cautions | Long-acting beta agonist: arrhythmia, worse atrial fibrillation. Antimuscarinic: dry mouth, anticholinergic burden in elders. Inhaled steroid: never alone, pneumonia, fractures. Albuterol: not excessively. Oral steroids: exacerbations only. |
| Older adults | Fixed 0.70 ratio may overdiagnose; arthritis, tremor, cognition, low flow limit dry powder inhalers → spacer, soft mist, nebulizer; refer to rehabilitation actively; palliative care early. |
| Oxygen | Treat arterial oxygen <55 mmHg or saturation <88%. Rest ≤88% → long-term oxygen >15 hours/day; rest 89–93% → none; exertion ≤88% → with exertion; night only → sleep apnea workup. |
| Refer to pulmonology | Uncertain diagnosis, early onset or deficiency, exacerbations despite optimal therapy, oxygen, noninvasive ventilation, surgery, symptoms out of proportion. |
| Term | What you need to know |
|---|---|
| Definition | Acute worsening over 14 days or less; exclude pneumonia, embolism, acute heart failure, pneumothorax. >80% outpatient. |
| Admit / intensive care | Admit: marked symptoms, noninvasive ventilation, new edema, arrhythmia, comorbidity, no home support. Intensive care: unstable, major infection, invasive ventilation, sepsis, altered mental status, acidosis. |
| Treat | Bronchodilators, steroids, oxygen; antibiotics if more and purulent sputum (doxycycline, macrolide, trimethoprim-sulfamethoxazole, amoxicillin-clavulanate; levofloxacin for pseudomonal concern); high-flow for hypoxia; noninvasive ventilation for hypercapnia. |
| Discharge | Albuterol no more than every 4 hours; stable 12–24 hours; walks across room; eats and sleeps; home arrangements. Recovery 4–6 weeks. |
| Term | What you need to know |
|---|---|
| ★ Study focus posted | He writes the exam items; his guidance is now slides 127–128 (the Study Focus table at the top of this sheet): about 20 questions on this lecture. |
| ★ Diagnostic restraint | Bronchitis is “our first opportunity to practice diagnostic restraint”: no routine antibiotics, whatever the sputum color. He closed on testing only when it changes a decision, and when to withhold antibiotics. |
| ★ Scores | Pneumonia Severity Index preferred for admission; CURB-65 complementary (0:56). |
| ★ Board favorites | Histoplasmosis (“going to show up on your PANCE”, the Physician Assistant National Certifying Exam); psittacosis (“super common medical boards question”). |
| Not tested (his words in the lecture) | Example chest films as “what is it”; influenza vaccine make-up; stage day ranges; the alveolar-arterial gradient (but his focus slide now says “steroid thresholds”: know 35 mm Hg or more too). Vaccine product selection, RSV eligibility and pneumococcal sequencing ARE on his focus slide. |
| Term | What you need to know |
|---|---|
| What it is | Self-limited viral infection of the large airways; cough (worst in the morning) 2–3 weeks, sometimes wheeze; clinical diagnosis. |
| Exam | Central wheeze; rhonchi that clear with cough; chest-wall tenderness; no consolidation (if present, think pneumonia). |
| Tests | No routine complete blood count, sputum culture or film; image if vital signs, focal findings or risk suggest pneumonia. Pertussis: test with paroxysms, post-tussive vomiting, whoop or exposure; don’t wait 4 weeks. |
| Treat | Expectations, rest, fluids, acetaminophen (check combination products); no routine antibiotics, codeine or steroids; bronchodilator trial if wheezing. Delayed “pocket” prescription. |
| Return if | Dyspnea, hemoptysis, persistent fever, hypoxemia, worse after improving. |
| Term | What you need to know |
|---|---|
| Most common cause | S. pneumoniae; highest incidence over 65; atypicals Mycoplasma, C. pneumoniae, Legionella (cruises, hot tubs, fountains). |
| Presentation | Higher fever, chills, pleuritic pain, productive cough, tachypnea; one lobe of crackles, dullness, egophony (E to A), whispered pectoriloquy, increased fremitus. |
| Confirm | Chest radiograph (ultrasound with expertise); cultures only for severe disease, resistance risk or failure; computed tomography for uncertainty, cavitation, non-homogeneous opacity, hidden lower lobes. |
| General care | Oxygen, fluids, sepsis care; narrow daily; no routine steroids in nonsevere pneumonia; steroids considered in severe community-acquired pneumonia except influenza pneumonia; drain complicated effusion or empyema. |
| Viral-positive | Outpatient without comorbidities: may skip antibiotics with close follow-up; with comorbidities or hospitalized: still treat. |
| Ventilator pneumonia | Pseudomonas and multidrug-resistant organisms, higher mortality; prevent: early extubation, hand hygiene, sterile technique, fewer circuit changes, head of bed up, mouth care, secretion drainage. |
| Pseudomonas | Moxifloxacin and ertapenem are not reliable; MRSA: vancomycin or linezolid. |
| Term | What you need to know |
|---|---|
| Risk | Dysphagia, altered consciousness, impaired airway protection (stroke, seizure); assess swallowing, oral hygiene, positioning. |
| Abscess picture | Weeks of fever, sweats, foul-smelling purulent sputum, hemoptysis; amphoric breath sounds (like breathing across an open jar); cavity with an air-fluid level. |
| Abscess treatment | Starts with antibiotics: intravenous ampicillin/sulbactam, then oral amoxicillin/clavulanate, several weeks; clindamycin reserved (C. difficile); computed tomography, bronchoscopy for obstruction or failure; drainage or surgery for large or refractory. |
| Term | What you need to know |
|---|---|
| Pneumocystis | Most common opportunistic infection in HIV; exertional dyspnea and dry cough (95% each), fever; up to half normal exam; bilateral perihilar infiltrates. Induced sputum or bronchoalveolar lavage microscopy or polymerase chain reaction; negative induced sputum → lavage; lactate dehydrogenase nonspecific; treat while confirming if suspicion is high. |
| Histoplasmosis | Soil, bird or bat droppings; Ohio and Mississippi River valleys; fever, dry cough, chest pain, headache 3–17 days later; urine antigen (cross-reacts with Blastomyces; repeat if early negative). |
| Cryptococcosis | Environmental inhalation; HIV, transplant, steroids, but also healthy hosts; mimics CAP, tuberculosis, cancer; serum cryptococcal antigen; lumbar puncture to look for central nervous system spread. |
| Psittacosis | Chlamydia psittaci from birds (pet shop, zoo, poultry); severe headache, photophobia, epistaxis, relative bradycardia, splenomegaly, Horder spots (rose-spot-like facial macules); nucleic acid amplification test or polymerase chain reaction (routine culture misses it); unilateral lower-lobe infiltrate. Doxycycline, 10–14 days after fever ends; macrolide with infectious disease if tetracyclines unsuitable; report to public health. |
| Mycoplasma | Children and young adults, outbreaks; gradual fever, persistent cough, headache. Macrolide or doxycycline (fluoroquinolone alternative); beta-lactams fail: no cell wall. No vaccine. |
| Term | What you need to know |
|---|---|
| Influenza basics | Orthomyxovirus, droplet nuclei; A most pathogenic; drift = gradual surface changes (yearly vaccine update), shift = reassortment (novel strains). Incubation 1–4 days; peaks mid-February. |
| Influenza picture | Sudden onset; fever 100–104 °F, myalgias, frontal or retro-orbital headache, sore throat (why most seek care), red watery eyes. |
| Influenza tests | Molecular preferred; a negative rapid antigen test does not exclude; don’t wait for results in hospitalized or high-risk patients; film in elderly or high-risk. |
| Influenza pneumonia | Rapid cough, dyspnea, cyanosis; primary viral or secondary bacterial (pneumococcal or staphylococcal). |
| COVID-19 picture | Inhaled particles indoors; incubation about 5 days; cough, dyspnea, fever, myalgia, headache; anosmia, dysgeusia less common; 18–33% asymptomatic. |
| COVID-19 tests | Nucleic acid amplification test (including polymerase chain reaction) most sensitive; negative antigen → repeat after 48 hours (2 tests if symptomatic, 3 if not) or a nucleic acid test; D-dimer alone does not diagnose thrombosis. |
| Term | What you need to know |
|---|---|
| ★ Three decisions | Is disease plausible? Could the patient be infectious? Which diagnostic and treatment pathway, and when to involve the health department or a specialist (3:09). |
| ★ The distinction | Infection versus disease “determines infectiousness, evaluation, and treatment” (3:07): latent infection is asymptomatic and not infectious. |
| ★ Study focus posted | His guidance is now slide 41 (the Study Focus table at the top of this sheet): about 10 questions on this lecture. |
| Watch out | He called fever and night sweats “pathognomonic”; the slide lists them as manifestations only, and symptoms may be absent. |
| Term | What you need to know |
|---|---|
| Biology | Acid-fast bacilli, lipid-rich walls with mycolic acids; slow growth (culture takes weeks, molecular tests are rapid); a smear cannot tell tuberculosis from nontuberculous species. |
| Species | M. tuberculosis complex (M. tuberculosis, M. bovis, M. africanum); nontuberculous: M. avium complex, M. kansasii, M. abscessus. |
| Spread | Pulmonary and laryngeal disease, by coughing, speaking, singing; shared indoor air, poor ventilation. Latent infection does not spread; extrapulmonary usually does not. |
| Pulmonary disease | Persistent cough, hemoptysis or pleuritic pain, fever, night sweats, weight loss; don’t wait 3 weeks in high-risk patients; a normal exam does not exclude it; children, elders and the immunocompromised present atypically. |
| Extrapulmonary | Nodes (painless enlargement), pleura (effusion), central nervous system (headache, altered mental status), spine (back pain, vertebral destruction), disseminated (fever, weight loss). |
| Differential | Nontuberculous mycobacteria, bacterial pneumonia or abscess, histoplasmosis and other endemic fungi, bronchiectasis, aspergillosis, lung cancer and other cavities. |
| Term | What you need to know |
|---|---|
| Before latent treatment | Exclude disease; a positive skin or blood test still needs evaluation for disease. |
| During treatment | Monthly review of adherence, symptoms, adverse effects; liver injury; cultures until conversion; skin and blood tests may stay positive (don’t use them to monitor). |
| After tuberculosis | Persistent dyspnea may be bronchiectasis; fibrotic lesions mean review prior treatment and exclude active disease; new symptoms mean reassess for recurrence. |
| Nontuberculous | Risk with bronchiectasis, chronic obstructive pulmonary disease, immune dysfunction; environmental; an isolate alone is not disease; other species need susceptibility-guided regimens. |